Surmodics (SRDX) 10-K 24 Nov 21 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Nov. 19, 2021	Mar. 31, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	SRDX
Security Exchange Name	NASDAQ
Entity Registrant Name	Surmodics, Inc
Entity Central Index Key	0000924717
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.05 par value
Entity File Number	0-23837
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-1356149
Entity Address, Address Line One	9924 West 74th Street
Entity Address, City or Town	Eden Prairie
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55344
City Area Code	952
Local Phone Number	500-7000
Document Annual Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		13,905,000
Entity Public Float			$ 752
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s Proxy Statement for the Registrant’s 2022 Annual Meeting of Shareholders are incorporated by reference into Part III.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Current Assets:
Cash and cash equivalents	$ 31,153	$ 30,785
Available-for-sale securities	7,717	30,313
Accounts receivable, net of allowances of $119 and $130 as of September 30, 2021 and 2020, respectively	9,169	7,675
Contract assets — royalties and license fees	7,091	6,108
Inventories, net	6,760	5,966
Income tax receivable	1,912	2,391
Prepaids and other	6,453	3,370
Total Current Assets	70,255	86,608
Property and equipment, net	30,090	30,103
Available-for-sale securities	2,002
Deferred income taxes	5,867	7,315
Intangible assets, net	37,054	13,283
Goodwill	45,606	27,185
Other assets	3,718	4,269
Total Assets	194,592	168,763
Current Liabilities:
Accounts payable	1,783	1,515
Accrued liabilities:
Compensation	8,480	6,630
Accrued other	4,905	5,547
Short-term borrowings	10,000
Deferred revenue	4,647	5,200
Total Current Liabilities	29,815	18,892
Deferred revenue, less current portion	10,301	10,796
Deferred income taxes	2,742
Other long-term liabilities	11,649	8,020
Total Liabilities	54,507	37,708
Commitments and Contingencies (Note 11)
Stockholders’ Equity:
Series A preferred stock — $.05 par value, 450 shares authorized; no shares issued and outstanding
Common stock — $.05 par value, 45,000 shares authorized; 13,899 and 13,672 shares issued and outstanding, as of September 30, 2021 and 2020, respectively	695	684
Additional paid-in capital	21,598	15,369
Accumulated other comprehensive income	1,727	3,174
Retained earnings	116,065	111,828
Total Stockholders’ Equity	140,085	131,055
Total Liabilities and Stockholders’ Equity	$ 194,592	$ 168,763

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Statement Of Financial Position [Abstract]
Allowances (accounts receivable)	$ 119	$ 130
Series A preferred stock, par value	$ 0.05	$ 0.05
Series A preferred stock, shares authorized	450,000	450,000
Series A preferred stock, shares issued	0	0
Series A preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	13,899,000	13,672,000
Common stock, shares outstanding	13,899,000	13,672,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Total revenue	$ 105,136	$ 94,864	$ 100,077
Operating costs and expenses:
Type of Cost, Good or Service [Extensible List]	Product Sales [Member]	Product Sales [Member]	Product Sales [Member]
Product costs	$ 17,177	$ 15,317	$ 13,639
Research and development	46,734	50,188	52,885
Selling, general and administrative	30,677	28,392	23,950
Acquired intangible asset amortization	2,793	2,218	2,405
Acquisition transaction, integration and other costs	1,049
Contingent consideration expense (gain)	3		(161)
Acquired in-process research and development			890
Total operating costs and expenses	98,433	96,115	93,608
Operating income (loss)	6,703	(1,251)	6,469
Other (expense) income:
Investment income, net	123	656	1,097
Interest expense	(310)	(133)	(152)
Foreign exchange (loss) gain	(170)	(248)	134
(Loss) gain on strategic investments and other		(478)	10
Other (expense) income	(357)	(203)	1,089
Income (loss) before income taxes	6,346	(1,454)	7,558
Income tax (provision) benefit	(2,109)	2,577	34
Net income	$ 4,237	$ 1,123	$ 7,592
Basic net income per share	$ 0.31	$ 0.08	$ 0.57
Diluted net income per share	$ 0.30	$ 0.08	$ 0.55
Weighted average number of shares outstanding:
Basic	13,765	13,552	13,389
Diluted	13,989	13,812	13,779
Product Sales [Member]
Revenue:
Total revenue	$ 46,478	$ 44,317	$ 40,219
Royalties and License Fees [Member]
Revenue:
Total revenue	47,056	40,634	48,458
Research, Development and Other [Member]
Revenue:
Total revenue	$ 11,602	$ 9,913	$ 11,400

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 4,237	$ 1,123	$ 7,592
Other comprehensive (loss) income:
Net changes related to available-for-sale securities, net of tax	1	(10)	64
Foreign currency translation adjustments	(1,448)	2,788	(2,386)
Other comprehensive (loss) income	(1,447)	2,778	(2,322)
Comprehensive income	$ 2,790	$ 3,901	$ 5,270

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Revision of Prior Period Change in Accounting Principle Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]	Retained Earnings [Member]Revision of Prior Period Change in Accounting Principle Adjustment [Member]
Beginning balance at Sep. 30, 2018	$ 108,610	$ 5,498	$ 670	$ 7,607	$ 2,718	$ 97,615	$ 5,498
Beginning balance, shares at Sep. 30, 2018			13,398,000
Accounting Standards Update [Extensible Enumeration]		us-gaap:AccountingStandardsUpdate201409Member					us-gaap:AccountingStandardsUpdate201409Member
Net income	7,592					7,592
Other comprehensive income (loss), net of tax	(2,322)				(2,322)
Issuance of common stock	441		$ 7	434
Issuance of common stock, shares			141,000
Common stock options exercised, net	$ 282		$ 1	281
Common stock options exercised, net, shares	13,000		12,000
Purchase of common stock to pay employee taxes	$ (2,662)		$ (3)	(2,659)
Purchase of common stock to pay employee taxes, shares			(47,000)
Stock-based compensation	5,077			5,077
Ending balance at Sep. 30, 2019	122,516		$ 675	10,740	396	110,705
Ending balance, shares at Sep. 30, 2019			13,504,000
Net income	1,123					1,123
Other comprehensive income (loss), net of tax	2,778				2,778
Issuance of common stock	500		$ 8	492
Issuance of common stock, shares			149,000
Common stock options exercised, net	$ 1,115		$ 3	1,112
Common stock options exercised, net, shares	125,000		64,000
Purchase of common stock to pay employee taxes	$ (2,430)		$ (2)	(2,428)
Purchase of common stock to pay employee taxes, shares			(45,000)
Stock-based compensation	5,453			5,453
Ending balance at Sep. 30, 2020	131,055		$ 684	15,369	3,174	111,828
Ending balance, shares at Sep. 30, 2020			13,672,000
Net income	4,237					4,237
Other comprehensive income (loss), net of tax	(1,447)				(1,447)
Issuance of common stock	619		$ 5	614
Issuance of common stock, shares			100,000
Common stock options exercised, net	$ 2,509		$ 7	2,502
Common stock options exercised, net, shares	248,000		146,000
Purchase of common stock to pay employee taxes	$ (2,751)		$ (1)	(2,750)
Purchase of common stock to pay employee taxes, shares			(19,000)
Stock-based compensation	5,863			5,863
Ending balance at Sep. 30, 2021	$ 140,085		$ 695	$ 21,598	$ 1,727	$ 116,065
Ending balance, shares at Sep. 30, 2021			13,899,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Operating Activities:
Net income	$ 4,237	$ 1,123	$ 7,592
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	8,017	7,263	7,312
Stock-based compensation	5,863	5,453	5,077
Noncash lease expense	308	246
Provision for credit losses	(11)	73	160
Deferred taxes	1,651	(1,139)	(1,088)
Payment of contingent consideration obligations in excess of acquisition-date value		(608)	(2,041)
Losses (gains) on strategic investments		479	(7)
Acquired in-process research and development			890
Impairment losses on intangible assets			259
Other	181	5	(170)
Change in operating assets and liabilities
Accounts receivable and contract asset	(2,480)	3,461	(1,630)
Inventories	(818)	(1,377)	(543)
Prepaids and other	(2,391)	410	(2,131)
Accounts payable	264	(483)	(765)
Accrued liabilities	1,406	1,847	(2,187)
Income taxes	210	(1,558)	822
Deferred revenue	(1,048)	(1,185)	(3,512)
Net cash provided by operating activities	15,389	14,010	8,038
Investing Activities:
Purchases of property and equipment	(5,279)	(3,671)	(5,998)
Payment for acquisition of intangible assets	(1,000)
Purchases of available-for-sale securities	(22,723)	(59,917)	(44,973)
Sales and maturities of available-for-sale securities	43,317	54,522	61,458
Purchase of business, net of acquired cash	(39,553)
Acquisition of in-process research and development			(750)
Other			17
Net cash (used in) provided by investing activities	(25,238)	(9,066)	9,754
Financing Activities:
Proceeds from short-term borrowings	10,000
Issuance of common stock	3,128	1,615	723
Payments for taxes related to net share settlement of equity awards	(2,751)	(2,534)	(2,688)
Payment of deferred financing costs		(137)
Payments for acquisition of in-process research and development	(150)	(1,000)
Payment of contingent consideration obligations		(2,592)	(9,064)
Net cash provided by (used in) financing activities	10,227	(4,648)	(11,029)
Effect of exchange rate changes on cash	(10)	128	(70)
Net change in cash and cash equivalents	368	424	6,693
Cash and Cash Equivalents:
Beginning of year	30,785	30,361	23,668
End of year	31,153	30,785	30,361
Supplemental Information:
Cash paid for income taxes	160	30	193
Cash paid for interest	74
Noncash financing and investing activities:
Acquisition of property and equipment and intangible assets, net of refundable credits in other current assets and liabilities	211	1,306	202
Right-of-use assets and property and equipment obtained in exchange for new operating lease liabilities	234	$ 1,181
Deferred and contingent consideration assumed in business acquisition	$ 4,071
Acquisition of in-process research and development in other long-term liabilities			140
Accrual of employee taxes on common stock exercises			$ 104

Description

Description	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Description	1. Description Surmodics, Inc. and subsidiaries (“Surmodics,” the “Company,” “we,” “us,” “our” and other like terms) is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (“IVD”) immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. Basis of Presentation The consolidated financial statements include all accounts and wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). All intercompany transactions have been eliminated. The Company operates on a fiscal year ending on September 30. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. Certain reclassifications have been made to the prior year's consolidated financial statements to conform to the current year presentation.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Select Balance Sheet Information	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Select Balance Sheet Information	2. Summary of Significant Accounting Policies and Select Balance Sheet Information Cash and Cash Equivalents Cash and cash equivalents consist of financial instruments with maturities of three months or less at the Company’s acquisition date of the security and are stated at cost which approximates fair value and may include money market instruments, certificates of deposit, repurchase agreements and commercial paper instruments. Accounts Receivable, Net We grant credit to customers in the normal course of business and maintain an allowance for credit losses. The allowance for credit losses reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. We consider various factors in establishing, monitoring and adjusting the allowance for credit losses including the aging of accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information. Investments As of September 30, 2021 and 2020 The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows: September 30, 2021 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 9,718 $ 2 $ (1 ) $ 9,719 $ 7,717 $ 2,002 Total $ 9,718 $ 2 $ (1 ) $ 9,719 $ 7,717 $ 2,002 September 30, 2020 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ — Total $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ — There were no held-to-maturity debt securities as of September 30, 2021 and 2020. There were no realized gains or losses on sales of available-for-sale securities for fiscal 2021, 2020 or 2019. Inventories Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead, with cost of product sales determined on a first-in, first-out basis. Inventories consisted of the following components: September 30, (In thousands) 2021 2020 Raw materials $ 4,165 $ 3,758 Work-in process 1,295 817 Finished products 1,300 1,391 Total $ 6,760 $ 5,966 Prepaids and Other Assets, Current Prepaids and other current assets consisted of the following: September 30, (In thousands) 2021 2020 Prepaid expenses $ 1,712 $ 1,418 Irish research and development credits receivable 1,164 1,177 CARES Act employee retention credit receivable 3,577 — Other — 775 Prepaids and other $ 6,453 $ 3,370 In fiscal 2021, a benefit of $3.6 million was recorded to reduce operating costs and expenses as a result of our eligibility for the employee retention credit under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") enacted in March 2020. This $3.6 million benefit and corresponding receivable reflect anticipated reimbursement of personnel expenses we incurred in fiscal 2021 and 2020. Property and Equipment Property and equipment are stated at cost, less any impairment, and are depreciated using the straight-line method over the estimated useful lives of the assets. The Company recorded depreciation expense of $4.9 million, $4.8 million and $4.7 million in fiscal 2021, 2020 and 2019, respectively. The September 30, 2021 and 2020 balances in construction-in-progress include the cost of equipment and building improvements not yet placed in service . As assets are placed in service, construction-in-progress is transferred to the specific property and equipment categories and depreciated over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the term of the lease or the estimated useful life of the asset. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. Property and equipment consisted of the following components: Useful Life September 30, (Dollars in thousands) (Years) 2021 2020 Land N/A $ 4,419 $ 4,419 Laboratory fixtures and equipment 3 to 10 29,482 28,600 Buildings and improvements 3 to 20 26,573 25,638 Leasehold improvements 5 to 10 6,499 4,836 Office furniture and equipment 3 to 10 8,713 7,334 Construction-in-progress 2,120 2,238 Less: Accumulated depreciation (47,716 ) (42,962 ) Property and equipment, net $ 30,090 $ 30,103 Intangible Assets Intangible assets consisted of the following: September 30, 2021 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,216 $ (8,878 ) $ 4,338 Developed technology 11.9 36,531 (5,652 ) 30,879 Patents and other 14.1 3,551 (2,294 ) 1,257 Total definite-lived intangible assets 53,298 (16,824 ) 36,474 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 53,878 $ (16,824 ) $ 37,054 September 30, 2020 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,356 $ (7,594 ) $ 5,762 Developed technology 11.5 9,685 (4,200 ) 5,485 Patents and other 14.1 3,551 (2,095 ) 1,456 Total definite-lived intangible assets 26,592 (13,889 ) 12,703 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 27,172 $ (13,889 ) $ 13,283 The Company recorded amortization expense of $3.1 million, $2.5 million and $2.6 million in fiscal 2021, 2020 and 2019, respectively. Based on the intangible assets in service as of September 30, 2021, estimated amortization expense for future fiscal years is as follows: (In thousands) 2022 $ 4,668 2023 4,070 2024 3,978 2025 3,940 2026 2,992 Thereafter 16,826 Definite-lived intangible assets $ 36,474 Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, changes in amortization periods, foreign currency exchange rates or other factors. The Company defines in-process research and development (“IPR&D”) as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business combination is recognized at fair value and is capitalized as an indefinite-lived intangible asset until completion or abandonment of the IPR&D project. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. In cases where the IPR&D projects are abandoned, the related IPR&D assets are written off. The Company assesses indefinite-lived assets for impairment annually in the fourth quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Similar to the goodwill impairment assessment, the indefinite-lived assets impairment assessment requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company performs its annual assessment of indefinite-lived intangible assets for impairment as of July 1 st in research and development expense . Goodwill Goodwill in the Medical Device reporting unit represents the gross value from the fiscal 2021 acquisition of Vetex Medical Limited (“Vetex”) and the fiscal 2016 acquisitions of Creagh Medical, Ltd. (“Creagh Medical”) and NorMedix, Inc. (“NorMedix”). Goodwill in the In Vitro Diagnostics reporting unit represents the gross value from the acquisition of BioFX Laboratories, Inc. in 2007. Refer to Note 12 Acquisitions for further disclosures for Vetex. Changes in the carrying amount of goodwill by segment were as follows: (In thousands) In Vitro Diagnostics Medical Device Total Goodwill as of September 30, 2019 $ 8,010 $ 18,161 $ 26,171 Foreign currency translation adjustment — 1,014 1,014 Goodwill as of September 30, 2020 8,010 19,175 27,185 Acquisition of Vetex Medical Limited — 19,089 19,089 Foreign currency translation adjustment — (668 ) (668 ) Goodwill as of September 30, 2021 $ 8,010 $ 37,596 $ 45,606 Goodwill represents the excess of the purchase price of an acquired business over the fair value assigned to the assets purchased and liabilities assumed. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s reporting units are the In Vitro Diagnostics and Medical Device reportable segments. Inherent in the determination of fair value of the reporting units are certain estimates and judgments, including the interpretation of current economic indicators and market valuations, as well as the Company’s strategic plans with regard to its operations. The Company performs its annual assessment of goodwill for impairment as of July 1 st The impairment assessment is reliant on forecasted cash flows, as well as the selected discount rate when a quantitative assessment is necessary, which are inherently subjective and require significant management estimates. Differences in the reporting units’ actual future operating results compared to these forecasted estimates could materially affect the estimation of the fair value of the reporting units. Goodwill was not impaired in either reporting unit based on the outcome of the fiscal 2021 annual impairment test which utilized a quantitative assessment. Other Assets, Noncurrent Other noncurrent assets consisted of the following: September 30, (In thousands) 2021 2020 Operating lease right-of-use assets $ 2,435 $ 2,508 Other noncurrent assets 1,283 1,761 Other assets, net $ 3,718 $ 4,269 Other noncurrent assets include prepaid expenses related to our ongoing clinical trials and a receivable related to refundable Irish research and development tax credits. Valuation of Long-lived Assets The Company periodically evaluates whether events and circumstances have occurred that may affect the estimated useful life or the recoverability of the remaining balance of long-lived assets, such as property and equipment, right-of-use assets, and definite-lived intangible assets. If such events or circumstances were to indicate that the carrying amount of these assets may not be recoverable, the Company would estimate the future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) were less than the carrying amount of the assets, the Company would recognize an impairment charge to reduce such assets to their fair value. In fiscal 2021, 2020 and 2019, there were no impairment charges relating to the Company’s long-lived assets as there were no events or circumstances that occurred that affected the recoverability of such assets. Accrued Other Liabilities Accrued other liabilities consisted of the following: September 30, (In thousands) 2021 2020 Accrued professional fees $ 489 $ 239 Accrued clinical study expense 1,667 2,206 Accrued purchases 1,195 647 Acquisition of in-process research and development and intangible assets 494 1,148 Due to customers 112 321 Construction-in-progress 23 272 Operating lease liability, current portion 518 436 Other 407 278 Total accrued other liabilities $ 4,905 $ 5,547 Other Long-term Liabilities Other long-term liabilities consisted of the following: September 30, (In thousands) 2021 2020 Deferred consideration (1) $ 5,106 $ 2,216 Contingent consideration (2) 817 — Unrecognized tax benefits (3) 2,538 2,464 Operating lease liabilities 3,188 3,340 Other long-term liabilities $ 11,649 $ 8,020 (1) Deferred consideration consists of the present value of guaranteed payments to be made in connection with the fiscal 2021 Vetex acquisition (Note 12) and with in-process R&D technology asset acquisitions in fiscal 2019 and 2018 (Note 11). (2) Contingent consideration consists of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 5 and Note 12). (3) Balance of unrecognized tax benefits (Note 9) includes accrued interest and penalties, if applicable. Revenue Recognition Revenue is recognized when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to receive in exchange for those goods or services. The Company primarily sells or licenses its products, technologies and services to other medical device and diagnostics companies. Revenue is recorded net of taxes collected from customers, and taxes collected are recorded as current liabilities until remitted to the relevant government authority. The amount of foreign taxes imposed on specific revenue producing transactions that is the responsibility of the Company is expensed as incurred and reported in income tax expense on the consolidated statements of operations. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. Performance Obligations We derive our revenue from three primary sources: Product Sales Royalties and License Fees Research, Development and Other IVD segment sales of chemical components: stabilization products, substrates, surface coatings and antigens to the diagnostic and biomedical research markets Medical Device segment royalties from licensing of our proprietary surface modification coating and medical device technologies to medical device manufacturers Medical Device segment commercial development feasibility services and contract coating services Medical Device segment sales of reagent chemicals to licensees Medical Device segment license fees primarily associated with the Abbott Agreement IVD segment commercial development services Medical Device segment sales of vascular intervention medical device products to original equipment manufacturer suppliers and distributors The Company recognizes revenue when control is transferred to the customer. The transfer of control varies by revenue classification and is described below. Product Sales . Revenue from product sales is recognized at the point in time control of the products is transferred, generally upon shipment based upon the standard contract terms. Shipping and handling activities are considered to be fulfillment activities rather than promised services and are not, therefore, considered to be separate performance obligations. The Company’s sales terms provide no right of return outside of a standard warranty policy, and returns are generally not significant. Payment terms for product sales are generally set at 30-45 days after shipment Royalties . Royalties revenue consists of sales-based and recurring minimum royalties earned under licenses of our surface modification coating technologies. Performance obligations under these licenses, which consist of the right to use the Company’s proprietary technology, are satisfied at a point in time corresponding with delivery of the underlying technology rights to the customer, which is generally upon transfer of the licensed technology to the customer. Sales-based royalties revenue represents variable consideration under the license agreements and is recognized in the period a customer sells products incorporating the Company’s licensed technologies. The Company estimates sales-based royalties revenue earned but unpaid at each reporting period using the expected value method based on historical sales information, adjusted for known changes such as product launches and patent expirations. The Company also considers macroeconomic factors affecting the medical device market. The Company's license arrangements also often provide for recurring fees (minimum royalties), which the Company recognizes at the later of the satisfaction of the underlying performance obligation or upon renewal of the contract, which generally occurs on a quarterly basis. Sales-based and minimum royalties are generally due within 45 days after the end of each quarter. License Fees . For distinct license performance obligations, upfront license fees are recognized when the Company satisfies the underlying performance obligation. This generally occurs upon transfer of the right to use the Company’s licensed technology to the customer, with the exception of the license of the Company’s SurVeil™ drug-coated balloon (the “ DCB”) disclosed below. Certain license arrangements include contingent milestone payments, which are due following achievement by our customers of specified sales or regulatory milestones. Contingent milestone payment terms vary by contract. The Company has generally fulfilled its performance obligation prior to achievement of these milestones. However, because of the uncertainty of the milestone achievement, and/or the dependence on sales of our customers, variable consideration for contingent milestones is fully constrained and excluded from the contract price until the milestone is achieved by our customer, to the extent collectability is reasonably certain. The Company has a collaborative arrangement contract with Abbott Vascular, Inc. (“Abbott”) disclosed in Note 4 Collaborative Arrangement (the “Abbott Agreement”). Under the Abbott Agreement, the Company has received payments totaling $60.8 million as of September 30, 2021 and may receive an additional contingent milestone payment of up to $30 million, pursuant to the terms of the Abbott Agreement. The performance obligation identified in the Abbott Agreement includes delivery of our licensed technology and completion of research and development activities, primarily clinical trial activities (together, “R&D and Clinical Activities”). These promises are not distinct performance obligations because the product necessary for completion of the R&D and Clinical Activities is currently only able to be manufactured by the Company due to the exclusive proprietary know-how and certain regulatory requirements associated with the manufacture of the product. SurVeil License fee r using the cost-to-cost method which measures progress based on costs incurred to date relative to the expected total cost of the services, as the Company believes this represents a faithful depiction of the satisfaction of its performance obligation. Revenue from the upfront fee and contingent clinical and regulatory milestone payments, once the underlying contingencies are achieved, is recognized within royalties and license fees on the consolidated statements of operations as the clinical and regulatory activities are performed on a proportional performance basis. Performance is measured based on actual costs incurred relative to the expected total cost of the underlying activities, most notably the completion of the TRANSCEND clinical trial. A significant component of the cost of this trial is the cost of the Company’s outsourced clinical trial clinical research organization (“CRO”) consultants, which is estimated based on executed statements of work, project budgets, and patient enrollment timing, among other factors. A significant change to the Company’s estimate of the costs to complete the TRANSCEND clinical trial could have a material effect on the Company’s results of operations. Significant judgment is used to estimate total revenue and cost at completion for this contract. To account for the Abbott Agreement, the Company applied the guidance in ASC Topic 808 (Collaborative Arrangements) as the parties are active participants and are exposed to significant risks and rewards dependent on commercial success of the collaborative activity. See Note 4 Collaborative Arrangement for further disclosures related to the Abbott Agreement. Research and Development . The Company performs research and development (“R&D”) activities as a service to customers, which are typically charged to customers on a time-and-materials basis. Generally, revenue for R&D services is recorded over time as the services are provided to the customer in the amount to which the Company has the right to invoice. These services are generally charged to the customer as they are provided. Payment terms for R&D services are generally set at 30-45 days. Contract Assets, Deferred Revenue and Remaining Performance Obligations Contract assets are generally short in duration given the nature of products produced and services provided by the Company. Contract assets consist of sales-based and minimum royalties revenue earned for which unconditional right to payment does not exist as of the balance sheet date. These assets are comprised of estimated sales-based royalties earned, but not yet reported by the Company’s customers, minimum royalties on non-cancellable contracts, and contingent milestones earned, but not yet billable based on the terms of the contract. See Note 3 Revenue for further contract asset disclosures. The Company records a contract liability, or deferred revenue, when there is an obligation to provide a product or service to the customer, and payment is received or due in advance of performance, or when payment is received for a period outside the contract term. See Note 4 Collaborative Arrangement for further deferred revenue disclosures. Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing, noncancellable contracts. For contracts that have an original duration of one year or less, the Company has elected the practical expedient applicable to such contracts and does not disclose the transaction price for remaining performance obligations at the end of each reporting period or the expecting timing of recognition of related revenue. See Note 4 Collaborative Arrangement for further performance obligation disclosures. Leases Effective in fiscal 2020 (October 1, 2019), the Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases The Company’s leases include one or more options to renew and extend the lease term at the Company’s discretion. These renewal options are not included in right-of-use assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options, and when they are reasonably certain to be exercised, the renewal period is included in the lease term. Operating lease right-of-use assets and lease liabilities were as follows: September 30, (In thousands) 2021 2020 Right-of-use assets: Other assets $ 2,435 $ 2,508 Operating lease liabilities: Other accrued liabilities $ 518 $ 436 Other long-term liabilities 3,188 3,340 Total operating lease liabilities $ 3,706 $ 3,776 As of September 30, 2021, operating lease maturities were as follows: (In thousands) 2022 $ 657 2023 671 2024 685 2025 699 2026 604 Thereafter 892 Total expected operating lease payments 4,208 Less: Imputed interest (502 ) Total operating lease liabilities $ 3,706 Operating lease cost was $0.8 million and $0.6 million for fiscal 2021 and 2020, respectively. Rent expense for fiscal 2019 was $0.5 million. Cash paid for operating lease liabilities approximated operating lease cost for fiscal 2021 and 2020. As of September 30, 2021, the weighted average remaining lease term for operating leases was 6.2 years, and the weighted average discount rate used to determine operating lease liabilities was 4.0%. Stock-based Compensation We measure the cost of employee services received in exchange for the award of equity instruments based on the fair value of the award at the date of grant. Share-based payments are expensed based on their grant-date fair values on a straight-line basis over the requisite service period of the total award, less estimated forfeitures based on historical experience. Shares awarded under the Company’s stock-based compensation plans, with the exception of restricted stock awards, are not considered issued or outstanding common stock of the Company until they vest and the shares are released. New awards and forfeitures of unvested restricted stock result in an increase (decrease), respectively, in common stock issued and outstanding. Research and Development R&D expenses include costs associated with the design, development, testing, enhancement and regulatory approval of the Company’s products. R&D expenses include employee compensation (including stock-based compensation), internal and external costs associated with our regulatory compliance and quality assurance functions, the costs of product used in development and clinical trials, consulting expenses, and facilities overhead. The Company also incurs significant R&D expenses to operate clinical trials. R&D costs are expensed as incurred. Certain R&D costs are related to customer contracts, and the related revenue is recognized as described in “Revenue Recognition” in this Note 2. Costs associated with customer-related R&D include specific project direct labor and materials expenses, as well as an allocation of overhead costs based on direct labor costs. Clinical Trial Costs. The Company sponsors clinical trials intended to obtain the necessary clinical data required to obtain approval from various regulatory agencies to market medical devices developed by the Company. Costs associated with clinical trials include trial design and management expenses, clinical site reimbursements and third-party fees, among other costs. The Company’s clinical trials are administered by third-party CROs. These CROs generally bill monthly for certain services performed, as well as upon achievement of certain milestones. The Company monitors patient enrollment, the progress of clinical studies, and related activities through internal reviews of data reported to the Company by the CROs and correspondence with the CROs. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate based on information received. These estimates often require significant judgement on the part of the Company’s management. Government Funding . In prior fiscal years, the Company has been eligible to receive reimbursement for certain qualifying R&D expenditures under a grant from the Industrial Development Agency of Ireland (“IDA”). Reimbursements are recognized as a reduction of R&D expense when there is reasonable assurance that the funding will be received and conditions associated with the funding are met. The Company recorded reimbursements from IDA grants of $0.8 million and $0.7 million in fiscal 2020 and 2019, respectively, as a reduction of R&D expense. Income Taxes We record a tax (provision) benefit for the anticipated tax consequences of the reported results of operations. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in this assessment. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in earnings in the period that includes the enactment date of such change. Net Income Per Share Data Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards and restricted stock units. The following table presents the denominator for the computation of diluted weighted average shares outstanding: Fiscal Year (In thousands) 2021 2020 2019 Basic weighted average shares outstanding 13,765 13,552 13,389 Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units 224 260 390 Diluted weighted average shares outstanding 13,989 13,812 13,779 The calculation of weighted average diluted shares outstanding excluded outstanding common stock options associated with the right to purchase less than 0.1 million shares for both fiscal 2021 and 2020 and 0.2 million shares for fiscal 2019, as their inclusion would have had an antidilutive effect on diluted net income per share for those periods. Business Combinations For acquisitions accounted for as business combinations, we record assets and liabilities acquired at their respective fair values as of the acquisition date. Contingent consideration is recognized at fair value as of the acquisition date, and changes in fair value are recognized in earnings until settlement. Acquisition-related transaction costs are expensed as incurred. Currency Translation The Company’s reporting currency is the U.S. dollar. Assets and liabilities of non-U.S. dollar functional currency subsidiaries are translated into U.S. dollars at the period-end exchange rates, and revenue and expenses are translated at the average quarterly exchange rates during the period. The net effect of these translation adjustments on the consolidated financial statements is recorded as a foreign currency translation adjustment, a component of accumulated other comprehensive income New Accounting Pronouncements Accounting Standards Recently Adopted Credit Losses. In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses, Measurement of Credit Losses on Financial Statements . This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Effective in fiscal 2021 (October 1, 2020), we adopted this guidance using the modified retrospective method. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. Income Taxes. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes , which eliminates certain exceptions related to the approach for intraperiod tax allocation and to the methodology for calculating taxes during the quarters, as well as clarifies the accounting for enacted changes in tax laws. Effective in fiscal 2021 (October 1, 2020), we adopted this guidance using a prospective approach. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. Leases. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASC Topic 842” or the “new lease accounting standard”). The standard maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees recognize a right-of-use asset and a lease liability on the consolidated balance sheets for those leases previously classified as operating leases under the previous guidance. The liability is equal to the present value of lease payments, while

Revenue

Revenue	12 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Revenue	3. Revenue The following table presents the Company’s revenues disaggregated by product classification and by reportable segment: Fiscal Year (In thousands) 2021 2020 2019 Medical Device Product sales $ 21,777 $ 21,608 $ 18,617 Royalties 30,781 28,614 34,781 License fees 16,275 12,020 13,678 Research, development and other 9,420 9,159 11,277 Medical Device Revenue 78,253 71,401 78,353 In Vitro Diagnostics Product sales 24,701 22,709 21,390 Other 2,182 754 334 In Vitro Diagnostics Revenue 26,883 23,463 21,724 Total Revenue $ 105,136 $ 94,864 $ 100,077 Contract assets totaled $7.1 million and $6.1 million as of September 30, 2021 and 2020, respectively. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 4 Collaborative Arrangement. Revenue from customers that equaled or exceeded 10% of total revenue was as follows: Fiscal Year 2021 2020 2019 Abbott 21 % 19 % 19 % Medtronic 13 % 14 % 14 %

Collaborative Arrangement

Collaborative Arrangement	12 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangement	4. Collaborative Arrangement On February 26, 2018, the Company entered into an agreement with Abbott whereby Abbott has exclusive worldwide commercialization rights for Surmodics' SurVeil TM SurVeil SurVeil SurVeil As of September 30, 2021, the Company has received payments totaling $60.8 million under the Abbott Agreement, which consist of the following: (i) $25 million upfront fee in fiscal 2018, (ii) $10 million milestone payment in fiscal 2019 upon completion of enrollment in the TRANSCEND clinical trial, (iii) $10.8 million milestone payment in fiscal 2020 upon receipt of Conformité Européenne Mark (“CE Mark”) approval prerequisite for commercialization of the SurVeil SurVeil Revenue recognized from the Abbott Agreement totaled $16.0 million, $12.0 million and $13.5 million in fiscal 2021, 2020 and 2019, respectively. As of September 30, 2021, the Company had recognized total license fee revenue of $45.9 million from the Abbott Agreement. Revenue recognized from the Abbott Agreement, which was included in the respective beginning of fiscal year balances of deferred revenue on the consolidated balance sheets, totaled $4.7 million, $5.0 million and $8.4 million for fiscal 2021, 2020 and 2019, respectively. As of September 30, 2021 and 2020, total deferred revenue from the upfront and milestone payments received of $14.9 million and $15.9 million, respectively, was recorded on the consolidated balance sheets. As of September 30, 2021, the estimated revenue expected to be recognized in future periods totaled approximately $14.9 million related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more. These remaining performance obligations relate to the Abbott Agreement, exclude the potential contingent milestone payment under the Abbott Agreement, and are expected to be recognized over the next four years as the services, which are primarily comprised of the R &D and Clinical Activities performance obligation in the Abbott Agreement See Note 2 for further information regarding revenue recognition for the Abbott Agreement.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements In determining the fair value of financial assets and liabilities, we utilize market data or other assumptions that we believe market participants would use in pricing the asset or liability in the principal or most advantageous market and adjust for non-performance and/or other risk associated with the company as well as counterparties, as appropriate. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those with fair value measurements that are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation. In valuing Level 3 assets and liabilities, we are required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The hierarchy gives the highest priority to Level 1, as this level provides the most reliable measure of fair value, while giving the lowest priority to Level 3. Assets and Liabilities Measured at Fair Value on a Recurring Basis Assets and liabilities measured at fair value on a recurring basis by level of the fair value hierarchy were as follows: September 30, 2021 (In thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Assets Cash equivalents (1) $ — $ 5,308 $ — $ 5,308 Available-for-sale investments (1) — 9,719 — 9,719 Total assets $ — $ 15,027 $ — $ 15,027 Liabilities Contingent consideration (2) $ — $ — $ 817 $ 817 Total liabilities $ — $ — $ 817 $ 817 September 30, 2020 (In thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Assets Cash equivalents (1) $ — $ 18,634 $ — $ 18,634 Available-for-sale investments (1) — 30,313 — 30,313 Total assets $ — $ 48,947 $ — $ 48,947 (1) Fair value of cash equivalents (money market funds) and available-for-sale investments (commercial paper and corporate bond securities) is based on quoted vendor prices and broker pricing where all significant inputs are observable. (2) Fair value of contingent consideration liabilities was determined based on discounted cash flow analyses that included probability and timing of development and regulatory milestone achievements and a discount rate, which are considered significant unobservable inputs as of the acquisition date and as of September 30, 2021. Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment and projected payment dates. Increases or decreases in the fair value of the contingent consideration liability can result from changes in the timing or likelihood of achieving milestones and changes in discount periods and rates. Projected contingent payment amounts are discounted back to the current period using a discount cash flow model. Interest accretion and fair value adjustments associated with contingent consideration liabilities are reported in contingent consideration expense (gain) on the consolidated statements of operations. Changes in the contingent consideration liabilities measured at fair value using Level 3 inputs were as follows: (In thousands) Contingent consideration liability at September 30, 2019 $ 3,200 Additions — Fair value adjustments — Settlements (3,200 ) Interest accretion — Foreign currency translation — Contingent consideration liability at September 30, 2020 — Additions 814 Fair value adjustments — Settlements — Interest accretion 3 Foreign currency translation — Contingent consideration liability at September 30, 2021 $ 817 As of September 30, 2021, the $0.8 million balance of contingent consideration liabilities associated with the acquisition of Vetex was included in other long-term liabilities on the consolidated balance sheets; see Note 12 Acquisitions for further disclosures. As of September 30, 2019, the $3.2 million balance of contingent consideration liabilities related to the fiscal 2016 acquisition of NorMedix, which was paid in fiscal 2020. Assets and Liabilities Measured at Fair Value on a Non-recurring Basis We measure certain assets at fair value on a non-recurring basis, primarily goodwill, intangible assets, and long-lived assets. These assets were initially measured and recognized at amounts equal to the fair value determined as of the date of acquisition or purchase and are subject to changes in value only for foreign currency translation and impairment. See Note 2 for additional information on impairment assessments and related Level 3 inputs for goodwill, indefinite-lived intangible assets and long-lived assets. Assets and Liabilities Not Measured at Fair Value Certain financial instruments are not measured at fair value but are recorded at carrying amounts approximating fair value based on their short-term nature. The carrying value of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximated fair value as of September 30, 2021 and 2020.

Debt

Debt	12 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	6. Debt On September 14, 2020 Availability under the Revolving Credit Facility is subject to a borrowing base that equals 80% of the margin value of securities collateral that has been pledged to Bridgewater. The Revolving Credit Facility was scheduled to mature on September 14, 2021, but the Company extended the maturity to September 14, 2022, as permitted under the Loan Agreement. The maturity date may be extended by the Company for up to one additional extension period of twelve months subject to certain conditions set forth in the Loan Agreement. The Company's obligations under the Loan Agreement are secured by substantially all of the Company’s and its material subsidiaries' assets, other than intellectual property, real estate and foreign assets, including equity in foreign subsidiaries. The Company has also pledged the stock of certain of its subsidiaries to secure such obligations. Interest under the Loan Agreement accrues at a rate per annum equal to the greater of (i) 3.25% per annum and (ii) the 90-day interest rate yield for U.S. Government Treasury Securities plus 2.75% per annum. A facility fee is payable on unused commitments at a rate of 0.075% quarterly. For fiscal 2021, unused commitment fees, reported within interest expense on the consolidated statements of operations, totaled $0.1 million. The Loan Agreement contains affirmative and negative covenants customary for a transaction of this type which, among other things, require the Company to meet certain financial tests, including (i) minimum liquidity, (ii) minimum current ratio , (iii) minimum adjusted EBITDA , and (iv) minimum tangible net worth. The Loan Agreement also contains covenants which, among other things, limit the Company's ability to incur additional debt, make certain investments, create or permit certain liens, create or permit restrictions on the ability of subsidiaries to pay dividends or make other distributions, consolidate or merge and engage in other activities customarily restricted in such agreements, in each case subject to exceptions permitted by the Loan Agreement. The Loan Agreement also contains customary events of default, the occurrence of which would permit the Bank to terminate its commitment and accelerate the Revolving Credit Facility .

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders' Equity	7. Stockholders’ Equity Repurchase of Common Stock Shares are repurchased from time to time to support the Company’s stock-based compensation programs and to return capital to stockholders. The Company accounts for repurchases of common stock using the par value method. On November 6, 2015, and on November 5, 2014, the Company’s Board of Directors authorized the repurchase of up to $20.0 million and $30.0 million, respectively, of the Company’s outstanding common stock in open-market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, tender offers or by any combination of such methods. The authorizations have no fixed expiration date. As of , million remained available to the Company for the purchase of its common stock under outstanding authorizations.

Stock-based Compensation Plans

Stock-based Compensation Plans	12 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation Plans	8. Stock-based Compensation Plans The Company has stock-based compensation plans under which it grants stock options, restricted stock awards, restricted stock units and deferred stock units. Stock-based compensation expense was reported as follows on the consolidated statements of operations: Fiscal Year (In thousands) 2021 2020 2019 Product costs $ 122 $ 119 $ 135 Research and development 1,298 896 876 Selling, general and administrative 4,443 4,438 4,066 Total stock-based compensation expense $ 5,863 $ 5,453 $ 5,077 As of September 30, 2021, approximately $8.4 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.2 years. Under the 2019 Equity Incentive Plan (“2019 Plan”), the Company is authorized to issue 1,100,000 shares, plus the number of shares pursuant to any awards granted under the 2009 Equity Incentive Plan (“2009 Plan”) that were outstanding on the effective date of the 2019 Plan that expire, are cancelled or forfeited, or are settled for cash. As of September 30, 2021, there were approximately 485,000 shares available for future equity awards under the 2019 Plan, including stock options, restricted stock, restricted stock units, and deferred stock units. Stock Option Awards The Company grants non-qualified stock options at fair market value on the grant date to certain key employees and members of the Board. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options as of the date of each grant. Stock option fair value assumptions and the weighted average fair value of stock options granted were as follows: Fiscal Year 2021 2020 2019 Stock option fair value assumptions: Risk-free interest rates 0.40 % 1.41 % 2.75 % Expected life (years) 4.6 4.6 4.5 Expected volatility 43 % 39 % 34 % Dividend yield — % — % — % Weighted average grant date fair value of stock options granted $ 14.71 $ 14.13 $ 17.89 The risk-free interest rate assumption is based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the awards. The expected life of options granted is determined based on the Company’s experience. Expected volatility is based on the Company’s stock price movement over a period approximating the expected term. Based on management’s judgment, dividend yields are expected to be zero for the expected life of the options. With respect to members of the Board, non-qualified stock options generally become exercisable on a monthly pro-rata basis within the one-year As of September 30, 2021, the aggregate intrinsic value of the option shares outstanding and option shares exercisable was $15.1 million and $7.9 million, respectively. As of September 30, 2021, the weighted average remaining contractual life of options outstanding and options exercisable was 4.6 years and 3.4 years, respectively. The total pre-tax intrinsic value of options exercised was $7.1 million, $2.0 million and $0.3 million in fiscal 2021, 2020 and 2019, respectively. The intrinsic value represents the difference between the exercise price and the fair market value of the Company’s common stock on the last day of the respective fiscal year end. Stock option activity was as follows: (In thousands, except per share data) Number of Shares Weighted Average Exercise Price Options outstanding at September 30, 2018 711 $ 26.28 Granted 179 55.09 Exercised (13 ) 22.03 Forfeited and expired (6 ) 42.28 Options outstanding at September 30, 2019 871 32.18 Granted 299 41.06 Exercised (125 ) 22.89 Forfeited and expired (105 ) 41.69 Options outstanding at September 30, 2020 940 35.18 Granted 274 40.95 Exercised (248 ) 24.22 Forfeited and expired (44 ) 44.58 Options outstanding at September 30, 2021 922 39.39 Options vested and exercisable at September 30, 2021 402 $ 36.07 Restricted Stock Awards The Company has entered into restricted stock agreements with certain key employees, covering the issuance of common stock (“Restricted Stock”). Restricted Stock generally vests at a 33% rate on each of the first three anniversaries following the grant date. Restricted Stock is released to employees if they are employed by the Company at the end of the vesting period. Restricted Stock is valued based on the market value of the shares as of the date of grant with the value allocated to expense evenly over the vesting period. The stock-based compensation table above includes Restricted Stock expenses recognized related to these awards, which totaled $2.2 million, $2.0 million and $1.7 million in fiscal 2021, 2020 and 2019, respectively. Restricted Stock activity was as follows: (In thousands, except per share data) Number of Shares Weighted Average Grant Date Fair Value Unvested restricted stock awards at September 30, 2018 85 $ 30.30 Granted 45 56.05 Vested (39 ) 28.61 Forfeited (1 ) 47.86 Unvested restricted stock awards at September 30, 2019 90 43.69 Granted 67 41.40 Vested (43 ) 38.74 Forfeited (14 ) 44.76 Unvested restricted stock awards at September 30, 2020 100 44.16 Granted 71 38.83 Vested (48 ) 44.07 Forfeited (4 ) 40.45 Unvested restricted stock awards at September 30, 2021 119 $ 41.14 Restricted Stock Units and Deferred Stock Units The Company has entered into restricted stock unit agreements with certain key employees in foreign jurisdictions and members of the Board, covering the issuance of common stock (“RSUs”). With respect to employees, RSUs generally vest at a 33% rate on each of the first three anniversaries following the grant date, and RSUs are settled in shares and issued to the employees if they are employed by the Company at the end of the vesting period. With respect to members of the Board, RSUs vest on a monthly pro-rata basis within the one-year period following the date of grant, and RSUs are settled in shares and generally issued upon termination of service as a Board member. RSUs are valued based on the market value of the shares as of the date of grant with the value allocated to expense evenly over the vesting period. The Company awarded approximately 17,000, 18,000 and 12,000 RSUs in fiscal 2021, 2020 and 2019, respectively. As of September 30, 2021 and 2020, outstanding RSUs (including unvested units and vested units not yet settled) totaled approximately 61,000 and 65,000 units, respectively, with a weighted average grant date fair value per unit of $33.45 and $31.12, respectively. The stock-based compensation table above includes RSU expenses recognized related to these awards, which totaled $0.5 million, $0.6 million and $0.6 million in fiscal 2021, 2020 and 2019, respectively. Directors may elect to receive their annual fees for services to the Board in deferred stock units (“DSUs”). DSUs are fully vested and expensed upon grant at the market value of the shares on the grant date. DSUs are settled in shares and issued to the Director upon termination of service as a Board member. As of September 30, 2021 and 2020, outstanding, fully vested DSUs totaled approximately 34,000 and 33,000 units, respectively, with a weighted average grant date fair value per unit of $30.32 and $28.41, respectively. The stock-based compensation table above includes DSU expenses recognized related to these awards, which totaled $0.1 million per year in each of fiscal 2021, 2020 and 2019. Performance Share Awards In fiscal 2017 and prior years, the Company entered into performance share agreements with certain key employees covering the issuance of common stock (“Performance Shares”). The Organization and Compensation Committee of the Board of Directors (the “Committee”) established cumulative revenue and cumulative earnings before interest, income taxes, depreciation and amortization (“EBITDA”) for the applicable three-year 1999 Employee Stock Purchase Plan Under the amended 1999 Employee Stock Purchase Plan (“ESPP”), the Company is authorized to issue up to 600,000 shares of common stock. All full-time and part-time U.S. employees can elect to have up to 10% of their annual compensation withheld, with an annual limit of $25,000, to purchase the Company’s common stock at purchase prices defined within the provisions of the ESPP. ESPP share awards are valued based on the value of the discount feature plus the fair value of the optional features as of the date of grant using the Black-Scholes valuation model. The value of these share awards is allocated to expense evenly over each six-month purchase period. Employee contributions to the ESPP included in accrued liabilities on the consolidated balance sheets totaled $0.1 million as of both September 30, 2021 and 2020. The stock-based compensation table above includes expenses recognized related to the ESPP, which totaled $0.2 million, $0.2 million and $0.1 million for fiscal 2021, 2020 and 2019, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes Income taxes on the consolidated statements of operations consisted of the following: Fiscal Year (In thousands) 2021 2020 2019 Current provision (benefit): U.S. Federal $ 263 $ (1,570 ) $ 1,355 U.S. State 108 42 192 International 87 90 41 Total current provision (benefit) 458 (1,438 ) 1,588 Deferred provision (benefit): U.S. Federal 1,851 (1,336 ) (1,505 ) U.S. State (62 ) 197 (117 ) International (138 ) — — Total deferred benefit 1,651 (1,139 ) (1,622 ) Total income tax provision (benefit) $ 2,109 $ (2,577 ) $ (34 ) The difference between amounts calculated at the statutory U.S. federal income tax rate of 21% and the Company’s effective tax rate was as follows: Fiscal Year (In thousands) 2021 2020 2019 Amount at statutory U.S. federal income tax rate $ 1,333 $ (305 ) $ 1,587 Change because of the following items: State income taxes, net of federal benefit (273 ) (551 ) (452 ) U.S. federal and foreign R&D credits (920 ) (1,571 ) (2,464 ) Foreign and state rate differential 596 212 156 Valuation allowance change 1,059 825 671 Stock-based compensation (1) (544 ) (81 ) (163 ) Contingent consideration expense (gain) and related foreign currency revaluation 3 — (61 ) U.S. Federal and state rate change (35 ) 17 44 Tax reserve change (150 ) 609 770 Foreign-derived income deduction — (88 ) (150 ) Impact of CARES Act 735 (1,700 ) — Acquisition-related transaction costs 187 — — Other 118 56 28 Income tax provision (benefit) $ 2,109 $ (2,577 ) $ (34 ) (1) Includes non-deductible stock-based compensation. In March 2020, the CARES Act was enacted and included significant business tax provisions. In particular, the CARES Act modified the rules associated with net operating losses (“NOLs”) and made technical corrections to tax depreciation methods for qualified improvement property. Under the temporary provisions of CARES Act, NOL carryforwards and carrybacks may offset 100% of taxable income for taxable years beginning before 2021. In addition, NOLs arising in 2018, 2019 and 2020 taxable years may be carried back to each of the preceding five years to generate a refund. In fiscal 2020, the income tax benefit included a discrete tax benefit of $1.7 million as a result of our ability under the CARES Act to carry back NOLs incurred to periods when the statutory tax rate was 35% versus our current tax rate of 21%. Excess tax benefits related to stock-based compensation expense are recorded within income tax (provision) benefit on the consolidated statements of operations and totaled $0.9 million, $0.4 million and $0.5 million for fiscal 2021, 2020 and 2019, respectively. The components of deferred income taxes, net, consisted of the following and resulted from differences in the recognition of transactions for income tax and financial reporting purposes: September 30, (In thousands) 2021 2020 Depreciable assets $ (5,106 ) $ (1,964 ) Deferred revenue 2,130 2,029 Accruals and reserves 1,572 1,858 Stock-based compensation 1,997 2,232 Impaired strategic investments 1,782 1,767 NOL carryforwards 4,319 3,526 U.S. Federal and state R&D credits 3,066 3,216 Other 618 897 Valuation allowance (7,253 ) (6,246 ) Deferred taxes, net $ 3,125 $ 7,315 As of September 30, 2021 and 2020, deferred tax asset valuation allowances totaled $7.3 million and $6.2 million, respectively. The valuation allowances were primarily related to other-than-temporary impairment losses on strategic investments, state R&D credit carryforwards, and NOL carryforwards of Creagh Medical. As of September 30, 2021, the Company had federal and state R&D credit carryforwards of $3.1 million that will begin expiring in fiscal 2029. As of September 30, 2021, the Company had U.S. federal and state NOL carryforwards of $0.1 million and $0.1 million tax-effected, respectively, that will begin expiring in fiscal 2035 and fiscal 2029, respectively. Ireland NOL carryforward tax assets totaled $4.1 million as of September 30, 2021, much of which was acquired as part of the Creagh Medical acquisition in fiscal 2016 and the Vetex acquisition in fiscal 2021, and have an unlimited carryforward period. Unrecognized tax benefits are the differences between a tax position taken, or expected to be taken in a tax return, and the benefit recognized for accounting purposes pursuant to accounting guidance. The following is a reconciliation of the changes in unrecognized tax benefits, excluding interest and penalties: Fiscal Year (In thousands) 2021 2020 2019 Unrecognized tax benefits, beginning balance $ 2,871 $ 2,323 $ 1,559 Increases in tax positions for prior years 15 58 278 Decreases in tax positions for prior years (8 ) (1 ) (2 ) Increases in tax positions for current year 458 664 735 Settlements with taxing authorities — — — Lapse of the statute of limitations (449 ) (173 ) (247 ) Unrecognized tax benefits, ending balance $ 2,887 $ 2,871 $ 2,323 The total amount of unrecognized tax benefits excluding interest and penalties that, if recognized, would affect the effective tax rate was $2.7 million, $2.7 million and $2.1 million as of September 30, 2021, 2020 and 2019, respectively. Currently, the Company does not expect the liability for unrecognized tax benefits to change significantly in the next 12 months and has classified the above balances on the consolidated balance sheets in other noncurrent liabilities. Interest and penalties related to unrecognized tax benefits are recorded in income tax expense. As of September 30, 2021, 2020 and 2019, the gross amount accrued for interest and penalties on unrecognized tax benefits was $0.4 million, $0.6 million and $0.5 million, respectively. The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions, as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. U.S. federal income tax returns for years prior to fiscal 2018 are no longer subject to examination by federal tax authorities. For tax returns for U.S. state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2010. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2017. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical, NorMedix and Vetex for periods prior to the respective acquisition dates, pursuant to the terms of the related share purchase agreements. As of September 30, 2021 and 2020, there were no undistributed earnings in foreign subsidiaries.

Defined Contribution Plans

Defined Contribution Plans	12 Months Ended
	Sep. 30, 2021
Compensation And Retirement Disclosure [Abstract]
Defined Contribution Plans	10. Defined Contribution Plans The Company has a 401(k) retirement and savings plan for the benefit of qualifying U.S. employees, and a defined contribution Personal Retirement Savings Account plan for the benefit of qualifying Ireland employees. For U.S. employees, the Company matches 50% of employee contributions on the first 6% of eligible compensation. For eligible Ireland employees, the Company makes contributions of up to 8% of eligible compensation on employee contributions of up to 6% of eligible compensation. Expense recognized for Company contributions to defined contribution plans totaled $1.1 million, $1.0 million and $0.9 million in fiscal 2021, 2020 and 2019, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Litigation. From time to time, the Company may become involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which if granted, could require significant expenditures or result in lost revenue. The Company records a liability on the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded Clinical Trials. The Company has engaged CRO consultants to assist with the administration of its ongoing clinical trials. The Company has executed separate contracts with two CROs for services rendered in connection with the TRANSCEND pivotal clinical trial for the DCB, including pass-through expenses paid by the CROs, of up to $29 million in the aggregate. As of September 30, 2021, an estimated $7 million remains to be paid on these contracts, which may vary depending on actual pass-through expenses incurred to execute the trial. The Company estimates that the total cost of the TRANSCEND clinical trial will be in the range of $37 million to $40 million from inception to completion. In the event the Company were to terminate any trial, it may incur certain financial penalties, which would become payable to the CRO for costs to wind down the terminated trial. Asset Acquisitions. In fiscal 2019, the Company acquired certain intellectual property assets to support ongoing development of the Company’s medical device pipeline and paid the sellers $0.8 million in fiscal 2019 and $0.2 million in fiscal 2021. An additional $1.1 million in payments is contingent upon achievement of certain strategic milestones within a contingency period ending in 2022. In fiscal 2019, the Company recorded a charge totaling $0.9 million related to this acquisition in acquired IPR&D expense on the consolidated statements of operations. In fiscal 2018, the Company acquired certain intellectual property assets of Embolitech, LLC (the “Embolitech Transaction”). As part of the Embolitech Transaction, the Company paid the sellers $5.0 million in fiscal 2018, $1.0 million in fiscal 2020 and $1.0 million in fiscal 2021. The Company is obligated to pay additional installments totaling $2.5 million fiscal 2022 through fiscal 2024. These payments may be accelerated upon the occurrence of certain sales and regulatory milestones. An additional $1.0 million payment is contingent upon the achievement of a certain regulatory milestone within a contingency period ending in 2033. Business Combinations. See Note 12 Acquisitions for disclosure of the fiscal 2021 acquisition of Vetex and associated deferred and contingent consideration liabilities. As of September 30, 2021

Acquisitions

Acquisitions	12 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Acquisitions	12. Acquisitions Vetex Medical Limited On July 2, 2021, Surmodics acquired all of the outstanding shares of Vetex Medical Limited (“Vetex”). Vetex, which was formerly privately held and is based in Galway, Ireland, develops and manufactures medical devices focused on venous clot removal solutions. The transaction expands Surmodics’ thrombectomy portfolio with a second FDA 510(k)-cleared device, a mechanical venous thrombectomy device. The acquisition was accounted for as a business combination. The acquired assets, liabilities and operating results of Vetex have been included on our consolidated financial statements within the Medical Device segment from the date of acquisition. Surmodics acquired Vetex with an upfront cash payment of $39.9 million funded using cash on hand and $10.0 million from the Revolving Credit Facility. The Company is obligated to pay additional installments totaling $3.5 million in fiscal 2024 through fiscal 2027. These payments may be accelerated upon the occurrence of certain product development and regulatory milestones. An additional $3.5 million in payments is contingent upon the achievement of certain product development and regulatory milestones within a contingency period ending in fiscal 2027. The acquisition date fair value of purchase consideration was as follows: (In thousands) Consideration paid at closing $ 39,985 Deferred consideration 3,257 Contingent consideration 814 Total purchase consideration 44,056 Less: Cash acquired (432 ) Total purchase consideration, net of cash acquired $ 43,624 The fair value of contingent consideration was derived using a discounted cash flow approach based on Level 3 inputs. See Note 5 Fair Value Measurements for additional disclosures regarding contingent consideration. As of September 30, 2021, the preliminary allocation of purchase consideration was as follows: (In thousands) Asset (Liability) Current assets $ 66 Property and equipment 37 Intangible assets 27,600 Other non-current assets 133 Accrued compensation (236 ) Other accrued liabilities (111 ) Deferred income taxes (2,954 ) Net assets acquired 24,535 Goodwill 19,089 Total purchase consideration, net of cash acquired $ 43,624 The allocation of purchase consideration is considered preliminary as of September 30, 2021 with provisional amounts related to current assets, other non-current assets and deferred income taxes. We expect to finalize the allocation of purchase consideration no later than one year from the acquisition date. Acquired intangible assets consist of developed technology. We used the income approach, specifically the discounted cash flow method and the incremental cash flow approach using Level 3 inputs, to derive the fair value of the developed technology. The developed technology is amortized on a straight-line basis over its estimated useful life of 12 years. The amortization of the acquired intangible assets is tax deductible. The goodwill recorded from the Vetex acquisition is a result of expected synergies from integrating the Vetex business into the Company’s Medical Device segment and from acquiring and retaining the existing Vetex workforce. The goodwill is not deductible for tax purposes. In fiscal 2021, we reported zero revenue and $(0.9) million net loss from Vetex in our consolidated statements of operations. In addition, in fiscal 2021, we recognized $1.0 million in acquisition transaction, integration and other costs related to the Vetex acquisition on the consolidated statements of operations. The pro forma impact of business combinations during fiscal years 2021, 2020 and 2019 was not significant, neither individually nor in the aggregate, to the consolidated results of the Company.

Reportable Segment Information

Reportable Segment Information	12 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Reportable Segment Information	13. Reportable Segment Information Reportable segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. We operate two reportable segments: • Medical Device: Manufacture of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices; drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and structural heart, among others; and the manufacture of interventional medical devices, including drug-coated balloons and mechanical thrombectomy devices, for peripheral arterial disease treatment and other applications; and • In Vitro Diagnostics: Manufacture of component products and technologies for diagnostic immunoassay as well as molecular test and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens. Segment revenue, operating income (loss), and depreciation and amortization were as follows: Fiscal Year (In thousands) 2021 2020 2019 Revenue: Medical Device $ 78,253 $ 71,401 $ 78,353 In Vitro Diagnostics 26,883 23,463 21,724 Total revenue $ 105,136 $ 94,864 $ 100,077 Operating income (loss): Medical Device $ 4,683 $ (3,246 ) $ 4,794 In Vitro Diagnostics 13,770 11,771 10,620 Total segment operating income 18,453 8,525 15,414 Corporate (11,750 ) (9,776 ) (8,945 ) Total operating income (loss) $ 6,703 $ (1,251 ) $ 6,469 Depreciation and amortization: Medical Device $ 7,224 $ 6,223 $ 5,811 In Vitro Diagnostics 395 483 464 Corporate 398 557 1,037 Total depreciation and amortization $ 8,017 $ 7,263 $ 7,312 The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments. Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available. Revenue by geographic region was as follows: Fiscal Year 2021 2020 2019 Domestic 79 % 78 % 81 % Foreign 21 % 22 % 19 % Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows: September 30, (In thousands) 2021 2020 U.S. $ 25,920 $ 25,273 Ireland 41,224 18,113

Schedule of Valuation and Quali

Schedule of Valuation and Qualifying Accounts	12 Months Ended
	Sep. 30, 2021
Valuation And Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts	Surmodics, Inc. Schedule II – Valuation and Qualifying Accounts (In thousands) Balance at Beginning of Fiscal Year Additions: Charges to Income Deductions: Other Changes (Debit) Credit Balance at End of Fiscal Year Allowance for credit losses: Fiscal year ended September 30, 2019 $ 147 $ 188 $ (135 ) (a) $ 200 Fiscal year ended September 30, 2020 200 73 (143 ) (a) 130 Fiscal year ended September 30, 2021 130 (11 ) — (a) 119 (a) Primarily consists of uncollectible accounts written off, less recoveries.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Select Balance Sheet Information (Policies)	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of financial instruments with maturities of three months or less at the Company’s acquisition date of the security and are stated at cost which approximates fair value and may include money market instruments, certificates of deposit, repurchase agreements and commercial paper instruments.
Accounts Receivable, Net	Accounts Receivable, Net We grant credit to customers in the normal course of business and maintain an allowance for credit losses. The allowance for credit losses reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. We consider various factors in establishing, monitoring and adjusting the allowance for credit losses including the aging of accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. We base our estimates of credit loss reserves on historical experience and adjust, as necessary, to reflect current conditions using reasonable and supportable forecasts not already reflected in the historical loss information.
Investments	Investments As of September 30, 2021 and 2020 The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows: September 30, 2021 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 9,718 $ 2 $ (1 ) $ 9,719 $ 7,717 $ 2,002 Total $ 9,718 $ 2 $ (1 ) $ 9,719 $ 7,717 $ 2,002 September 30, 2020 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ — Total $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ — There were no held-to-maturity debt securities as of September 30, 2021 and 2020. There were no realized gains or losses on sales of available-for-sale securities for fiscal 2021, 2020 or 2019.
Inventories	Inventories Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead, with cost of product sales determined on a first-in, first-out basis. Inventories consisted of the following components: September 30, (In thousands) 2021 2020 Raw materials $ 4,165 $ 3,758 Work-in process 1,295 817 Finished products 1,300 1,391 Total $ 6,760 $ 5,966
Prepaids and Other Current Assets, Current	Prepaids and Other Assets, Current Prepaids and other current assets consisted of the following: September 30, (In thousands) 2021 2020 Prepaid expenses $ 1,712 $ 1,418 Irish research and development credits receivable 1,164 1,177 CARES Act employee retention credit receivable 3,577 — Other — 775 Prepaids and other $ 6,453 $ 3,370 In fiscal 2021, a benefit of $3.6 million was recorded to reduce operating costs and expenses as a result of our eligibility for the employee retention credit under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") enacted in March 2020. This $3.6 million benefit and corresponding receivable reflect anticipated reimbursement of personnel expenses we incurred in fiscal 2021 and 2020.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less any impairment, and are depreciated using the straight-line method over the estimated useful lives of the assets. The Company recorded depreciation expense of $4.9 million, $4.8 million and $4.7 million in fiscal 2021, 2020 and 2019, respectively. The September 30, 2021 and 2020 balances in construction-in-progress include the cost of equipment and building improvements not yet placed in service . As assets are placed in service, construction-in-progress is transferred to the specific property and equipment categories and depreciated over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the term of the lease or the estimated useful life of the asset. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. Property and equipment consisted of the following components: Useful Life September 30, (Dollars in thousands) (Years) 2021 2020 Land N/A $ 4,419 $ 4,419 Laboratory fixtures and equipment 3 to 10 29,482 28,600 Buildings and improvements 3 to 20 26,573 25,638 Leasehold improvements 5 to 10 6,499 4,836 Office furniture and equipment 3 to 10 8,713 7,334 Construction-in-progress 2,120 2,238 Less: Accumulated depreciation (47,716 ) (42,962 ) Property and equipment, net $ 30,090 $ 30,103
Intangible Assets	Intangible Assets Intangible assets consisted of the following: September 30, 2021 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,216 $ (8,878 ) $ 4,338 Developed technology 11.9 36,531 (5,652 ) 30,879 Patents and other 14.1 3,551 (2,294 ) 1,257 Total definite-lived intangible assets 53,298 (16,824 ) 36,474 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 53,878 $ (16,824 ) $ 37,054 September 30, 2020 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,356 $ (7,594 ) $ 5,762 Developed technology 11.5 9,685 (4,200 ) 5,485 Patents and other 14.1 3,551 (2,095 ) 1,456 Total definite-lived intangible assets 26,592 (13,889 ) 12,703 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 27,172 $ (13,889 ) $ 13,283 The Company recorded amortization expense of $3.1 million, $2.5 million and $2.6 million in fiscal 2021, 2020 and 2019, respectively. Based on the intangible assets in service as of September 30, 2021, estimated amortization expense for future fiscal years is as follows: (In thousands) 2022 $ 4,668 2023 4,070 2024 3,978 2025 3,940 2026 2,992 Thereafter 16,826 Definite-lived intangible assets $ 36,474 Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, changes in amortization periods, foreign currency exchange rates or other factors. The Company defines in-process research and development (“IPR&D”) as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business combination is recognized at fair value and is capitalized as an indefinite-lived intangible asset until completion or abandonment of the IPR&D project. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. In cases where the IPR&D projects are abandoned, the related IPR&D assets are written off. The Company assesses indefinite-lived assets for impairment annually in the fourth quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Similar to the goodwill impairment assessment, the indefinite-lived assets impairment assessment requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company performs its annual assessment of indefinite-lived intangible assets for impairment as of July 1 st in research and development expense .
Goodwill	Goodwill Goodwill in the Medical Device reporting unit represents the gross value from the fiscal 2021 acquisition of Vetex Medical Limited (“Vetex”) and the fiscal 2016 acquisitions of Creagh Medical, Ltd. (“Creagh Medical”) and NorMedix, Inc. (“NorMedix”). Goodwill in the In Vitro Diagnostics reporting unit represents the gross value from the acquisition of BioFX Laboratories, Inc. in 2007. Refer to Note 12 Acquisitions for further disclosures for Vetex. Changes in the carrying amount of goodwill by segment were as follows: (In thousands) In Vitro Diagnostics Medical Device Total Goodwill as of September 30, 2019 $ 8,010 $ 18,161 $ 26,171 Foreign currency translation adjustment — 1,014 1,014 Goodwill as of September 30, 2020 8,010 19,175 27,185 Acquisition of Vetex Medical Limited — 19,089 19,089 Foreign currency translation adjustment — (668 ) (668 ) Goodwill as of September 30, 2021 $ 8,010 $ 37,596 $ 45,606 Goodwill represents the excess of the purchase price of an acquired business over the fair value assigned to the assets purchased and liabilities assumed. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s reporting units are the In Vitro Diagnostics and Medical Device reportable segments. Inherent in the determination of fair value of the reporting units are certain estimates and judgments, including the interpretation of current economic indicators and market valuations, as well as the Company’s strategic plans with regard to its operations. The Company performs its annual assessment of goodwill for impairment as of July 1 st The impairment assessment is reliant on forecasted cash flows, as well as the selected discount rate when a quantitative assessment is necessary, which are inherently subjective and require significant management estimates. Differences in the reporting units’ actual future operating results compared to these forecasted estimates could materially affect the estimation of the fair value of the reporting units. Goodwill was not impaired in either reporting unit based on the outcome of the fiscal 2021 annual impairment test which utilized a quantitative assessment.
Other Assets, Noncurrent	Other Assets, Noncurrent Other noncurrent assets consisted of the following: September 30, (In thousands) 2021 2020 Operating lease right-of-use assets $ 2,435 $ 2,508 Other noncurrent assets 1,283 1,761 Other assets, net $ 3,718 $ 4,269 Other noncurrent assets include prepaid expenses related to our ongoing clinical trials and a receivable related to refundable Irish research and development tax credits.
Valuation of Long-lived Assets	Valuation of Long-lived Assets The Company periodically evaluates whether events and circumstances have occurred that may affect the estimated useful life or the recoverability of the remaining balance of long-lived assets, such as property and equipment, right-of-use assets, and definite-lived intangible assets. If such events or circumstances were to indicate that the carrying amount of these assets may not be recoverable, the Company would estimate the future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) were less than the carrying amount of the assets, the Company would recognize an impairment charge to reduce such assets to their fair value. In fiscal 2021, 2020 and 2019, there were no impairment charges relating to the Company’s long-lived assets as there were no events or circumstances that occurred that affected the recoverability of such assets.
Accrued Other Liabilities	Accrued Other Liabilities Accrued other liabilities consisted of the following: September 30, (In thousands) 2021 2020 Accrued professional fees $ 489 $ 239 Accrued clinical study expense 1,667 2,206 Accrued purchases 1,195 647 Acquisition of in-process research and development and intangible assets 494 1,148 Due to customers 112 321 Construction-in-progress 23 272 Operating lease liability, current portion 518 436 Other 407 278 Total accrued other liabilities $ 4,905 $ 5,547
Other Long-term Liabilities	Other Long-term Liabilities Other long-term liabilities consisted of the following: September 30, (In thousands) 2021 2020 Deferred consideration (1) $ 5,106 $ 2,216 Contingent consideration (2) 817 — Unrecognized tax benefits (3) 2,538 2,464 Operating lease liabilities 3,188 3,340 Other long-term liabilities $ 11,649 $ 8,020 (1) Deferred consideration consists of the present value of guaranteed payments to be made in connection with the fiscal 2021 Vetex acquisition (Note 12) and with in-process R&D technology asset acquisitions in fiscal 2019 and 2018 (Note 11). (2) Contingent consideration consists of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 5 and Note 12). (3) Balance of unrecognized tax benefits (Note 9) includes accrued interest and penalties, if applicable.
Revenue Recognition	Revenue Recognition Revenue is recognized when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to receive in exchange for those goods or services. The Company primarily sells or licenses its products, technologies and services to other medical device and diagnostics companies. Revenue is recorded net of taxes collected from customers, and taxes collected are recorded as current liabilities until remitted to the relevant government authority. The amount of foreign taxes imposed on specific revenue producing transactions that is the responsibility of the Company is expensed as incurred and reported in income tax expense on the consolidated statements of operations. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. Performance Obligations We derive our revenue from three primary sources: Product Sales Royalties and License Fees Research, Development and Other IVD segment sales of chemical components: stabilization products, substrates, surface coatings and antigens to the diagnostic and biomedical research markets Medical Device segment royalties from licensing of our proprietary surface modification coating and medical device technologies to medical device manufacturers Medical Device segment commercial development feasibility services and contract coating services Medical Device segment sales of reagent chemicals to licensees Medical Device segment license fees primarily associated with the Abbott Agreement IVD segment commercial development services Medical Device segment sales of vascular intervention medical device products to original equipment manufacturer suppliers and distributors The Company recognizes revenue when control is transferred to the customer. The transfer of control varies by revenue classification and is described below. Product Sales . Revenue from product sales is recognized at the point in time control of the products is transferred, generally upon shipment based upon the standard contract terms. Shipping and handling activities are considered to be fulfillment activities rather than promised services and are not, therefore, considered to be separate performance obligations. The Company’s sales terms provide no right of return outside of a standard warranty policy, and returns are generally not significant. Payment terms for product sales are generally set at 30-45 days after shipment Royalties . Royalties revenue consists of sales-based and recurring minimum royalties earned under licenses of our surface modification coating technologies. Performance obligations under these licenses, which consist of the right to use the Company’s proprietary technology, are satisfied at a point in time corresponding with delivery of the underlying technology rights to the customer, which is generally upon transfer of the licensed technology to the customer. Sales-based royalties revenue represents variable consideration under the license agreements and is recognized in the period a customer sells products incorporating the Company’s licensed technologies. The Company estimates sales-based royalties revenue earned but unpaid at each reporting period using the expected value method based on historical sales information, adjusted for known changes such as product launches and patent expirations. The Company also considers macroeconomic factors affecting the medical device market. The Company's license arrangements also often provide for recurring fees (minimum royalties), which the Company recognizes at the later of the satisfaction of the underlying performance obligation or upon renewal of the contract, which generally occurs on a quarterly basis. Sales-based and minimum royalties are generally due within 45 days after the end of each quarter. License Fees . For distinct license performance obligations, upfront license fees are recognized when the Company satisfies the underlying performance obligation. This generally occurs upon transfer of the right to use the Company’s licensed technology to the customer, with the exception of the license of the Company’s SurVeil™ drug-coated balloon (the “ DCB”) disclosed below. Certain license arrangements include contingent milestone payments, which are due following achievement by our customers of specified sales or regulatory milestones. Contingent milestone payment terms vary by contract. The Company has generally fulfilled its performance obligation prior to achievement of these milestones. However, because of the uncertainty of the milestone achievement, and/or the dependence on sales of our customers, variable consideration for contingent milestones is fully constrained and excluded from the contract price until the milestone is achieved by our customer, to the extent collectability is reasonably certain. The Company has a collaborative arrangement contract with Abbott Vascular, Inc. (“Abbott”) disclosed in Note 4 Collaborative Arrangement (the “Abbott Agreement”). Under the Abbott Agreement, the Company has received payments totaling $60.8 million as of September 30, 2021 and may receive an additional contingent milestone payment of up to $30 million, pursuant to the terms of the Abbott Agreement. The performance obligation identified in the Abbott Agreement includes delivery of our licensed technology and completion of research and development activities, primarily clinical trial activities (together, “R&D and Clinical Activities”). These promises are not distinct performance obligations because the product necessary for completion of the R&D and Clinical Activities is currently only able to be manufactured by the Company due to the exclusive proprietary know-how and certain regulatory requirements associated with the manufacture of the product. SurVeil License fee r using the cost-to-cost method which measures progress based on costs incurred to date relative to the expected total cost of the services, as the Company believes this represents a faithful depiction of the satisfaction of its performance obligation. Revenue from the upfront fee and contingent clinical and regulatory milestone payments, once the underlying contingencies are achieved, is recognized within royalties and license fees on the consolidated statements of operations as the clinical and regulatory activities are performed on a proportional performance basis. Performance is measured based on actual costs incurred relative to the expected total cost of the underlying activities, most notably the completion of the TRANSCEND clinical trial. A significant component of the cost of this trial is the cost of the Company’s outsourced clinical trial clinical research organization (“CRO”) consultants, which is estimated based on executed statements of work, project budgets, and patient enrollment timing, among other factors. A significant change to the Company’s estimate of the costs to complete the TRANSCEND clinical trial could have a material effect on the Company’s results of operations. Significant judgment is used to estimate total revenue and cost at completion for this contract. To account for the Abbott Agreement, the Company applied the guidance in ASC Topic 808 (Collaborative Arrangements) as the parties are active participants and are exposed to significant risks and rewards dependent on commercial success of the collaborative activity. See Note 4 Collaborative Arrangement for further disclosures related to the Abbott Agreement. Research and Development . The Company performs research and development (“R&D”) activities as a service to customers, which are typically charged to customers on a time-and-materials basis. Generally, revenue for R&D services is recorded over time as the services are provided to the customer in the amount to which the Company has the right to invoice. These services are generally charged to the customer as they are provided. Payment terms for R&D services are generally set at 30-45 days. Contract Assets, Deferred Revenue and Remaining Performance Obligations Contract assets are generally short in duration given the nature of products produced and services provided by the Company. Contract assets consist of sales-based and minimum royalties revenue earned for which unconditional right to payment does not exist as of the balance sheet date. These assets are comprised of estimated sales-based royalties earned, but not yet reported by the Company’s customers, minimum royalties on non-cancellable contracts, and contingent milestones earned, but not yet billable based on the terms of the contract. See Note 3 Revenue for further contract asset disclosures. The Company records a contract liability, or deferred revenue, when there is an obligation to provide a product or service to the customer, and payment is received or due in advance of performance, or when payment is received for a period outside the contract term. See Note 4 Collaborative Arrangement for further deferred revenue disclosures. Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing, noncancellable contracts. For contracts that have an original duration of one year or less, the Company has elected the practical expedient applicable to such contracts and does not disclose the transaction price for remaining performance obligations at the end of each reporting period or the expecting timing of recognition of related revenue. See Note 4 Collaborative Arrangement for further performance obligation disclosures.
Leases	Leases Effective in fiscal 2020 (October 1, 2019), the Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases The Company’s leases include one or more options to renew and extend the lease term at the Company’s discretion. These renewal options are not included in right-of-use assets and lease liabilities as they are not reasonably certain of exercise. The Company regularly evaluates renewal options, and when they are reasonably certain to be exercised, the renewal period is included in the lease term. Operating lease right-of-use assets and lease liabilities were as follows: September 30, (In thousands) 2021 2020 Right-of-use assets: Other assets $ 2,435 $ 2,508 Operating lease liabilities: Other accrued liabilities $ 518 $ 436 Other long-term liabilities 3,188 3,340 Total operating lease liabilities $ 3,706 $ 3,776 As of September 30, 2021, operating lease maturities were as follows: (In thousands) 2022 $ 657 2023 671 2024 685 2025 699 2026 604 Thereafter 892 Total expected operating lease payments 4,208 Less: Imputed interest (502 ) Total operating lease liabilities $ 3,706 Operating lease cost was $0.8 million and $0.6 million for fiscal 2021 and 2020, respectively. Rent expense for fiscal 2019 was $0.5 million. Cash paid for operating lease liabilities approximated operating lease cost for fiscal 2021 and 2020. As of September 30, 2021, the weighted average remaining lease term for operating leases was 6.2 years, and the weighted average discount rate used to determine operating lease liabilities was 4.0%.
Stock-based Compensation	Stock-based Compensation We measure the cost of employee services received in exchange for the award of equity instruments based on the fair value of the award at the date of grant. Share-based payments are expensed based on their grant-date fair values on a straight-line basis over the requisite service period of the total award, less estimated forfeitures based on historical experience. Shares awarded under the Company’s stock-based compensation plans, with the exception of restricted stock awards, are not considered issued or outstanding common stock of the Company until they vest and the shares are released. New awards and forfeitures of unvested restricted stock result in an increase (decrease), respectively, in common stock issued and outstanding.
Research and Development	Research and Development R&D expenses include costs associated with the design, development, testing, enhancement and regulatory approval of the Company’s products. R&D expenses include employee compensation (including stock-based compensation), internal and external costs associated with our regulatory compliance and quality assurance functions, the costs of product used in development and clinical trials, consulting expenses, and facilities overhead. The Company also incurs significant R&D expenses to operate clinical trials. R&D costs are expensed as incurred. Certain R&D costs are related to customer contracts, and the related revenue is recognized as described in “Revenue Recognition” in this Note 2. Costs associated with customer-related R&D include specific project direct labor and materials expenses, as well as an allocation of overhead costs based on direct labor costs. Clinical Trial Costs. The Company sponsors clinical trials intended to obtain the necessary clinical data required to obtain approval from various regulatory agencies to market medical devices developed by the Company. Costs associated with clinical trials include trial design and management expenses, clinical site reimbursements and third-party fees, among other costs. The Company’s clinical trials are administered by third-party CROs. These CROs generally bill monthly for certain services performed, as well as upon achievement of certain milestones. The Company monitors patient enrollment, the progress of clinical studies, and related activities through internal reviews of data reported to the Company by the CROs and correspondence with the CROs. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate based on information received. These estimates often require significant judgement on the part of the Company’s management. Government Funding . In prior fiscal years, the Company has been eligible to receive reimbursement for certain qualifying R&D expenditures under a grant from the Industrial Development Agency of Ireland (“IDA”). Reimbursements are recognized as a reduction of R&D expense when there is reasonable assurance that the funding will be received and conditions associated with the funding are met. The Company recorded reimbursements from IDA grants of $0.8 million and $0.7 million in fiscal 2020 and 2019, respectively, as a reduction of R&D expense.
Income Taxes	Income Taxes We record a tax (provision) benefit for the anticipated tax consequences of the reported results of operations. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in this assessment. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in earnings in the period that includes the enactment date of such change.
Net Income Per Share Data	Net Income Per Share Data Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards and restricted stock units. The following table presents the denominator for the computation of diluted weighted average shares outstanding: Fiscal Year (In thousands) 2021 2020 2019 Basic weighted average shares outstanding 13,765 13,552 13,389 Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units 224 260 390 Diluted weighted average shares outstanding 13,989 13,812 13,779 The calculation of weighted average diluted shares outstanding excluded outstanding common stock options associated with the right to purchase less than 0.1 million shares for both fiscal 2021 and 2020 and 0.2 million shares for fiscal 2019, as their inclusion would have had an antidilutive effect on diluted net income per share for those periods.
Business Combinations	Business Combinations For acquisitions accounted for as business combinations, we record assets and liabilities acquired at their respective fair values as of the acquisition date. Contingent consideration is recognized at fair value as of the acquisition date, and changes in fair value are recognized in earnings until settlement. Acquisition-related transaction costs are expensed as incurred.
Currency Translation	Currency Translation The Company’s reporting currency is the U.S. dollar. Assets and liabilities of non-U.S. dollar functional currency subsidiaries are translated into U.S. dollars at the period-end exchange rates, and revenue and expenses are translated at the average quarterly exchange rates during the period. The net effect of these translation adjustments on the consolidated financial statements is recorded as a foreign currency translation adjustment, a component of accumulated other comprehensive income
New Accounting Pronouncements	New Accounting Pronouncements Accounting Standards Recently Adopted Credit Losses. In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses, Measurement of Credit Losses on Financial Statements . This ASU requires a financial asset (or a group of financial assets) measured at an amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Effective in fiscal 2021 (October 1, 2020), we adopted this guidance using the modified retrospective method. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. Income Taxes. In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes , which eliminates certain exceptions related to the approach for intraperiod tax allocation and to the methodology for calculating taxes during the quarters, as well as clarifies the accounting for enacted changes in tax laws. Effective in fiscal 2021 (October 1, 2020), we adopted this guidance using a prospective approach. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. Leases. In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASC Topic 842” or the “new lease accounting standard”). The standard maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees recognize a right-of-use asset and a lease liability on the consolidated balance sheets for those leases previously classified as operating leases under the previous guidance. The liability is equal to the present value of lease payments, while the asset is based on the liability, subject to adjustment, such as for direct costs. Effective in fiscal 2020 (October 1, 2019), the Company adopted the new lease accounting standard using the optional transition method which allowed us to continue to apply the guidance under the lease standard in effect at the time in the comparative periods presented. In addition, the Company elected the package of practical expedients, including opting not to reassess whether any existing contracts contain a lease, historical lease classification as operating or finance leases, or initial direct costs. The Company has also elected the practical expedient to not separate the lease and non-lease components for all classes of underlying assets. The Company elected the short-term lease recognition exemption for all leases that qualified and has accordingly excluded short-term leases from the recognition of right-of-use assets and lease liabilities. As a result of adoption of ASC Topic 842, we recorded operating lease right-of-use assets and corresponding operating lease liabilities of approximately $1.7 million and $2.9 million, respectively, as of October 1, 2019 with no impact on retained earnings. In addition, deferred rent liabilities related to escalating rent payments and tenant incentives totaling approximately $1.2 million were eliminated upon adoption, as these items were netted against right-of-use assets. The consolidated balance sheets for reporting periods beginning on or after October 1, 2019 are presented under the new guidance, while prior period amounts are not adjusted and continue to be reported in accordance with previous guidance. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s consolidated financial statements.
Reportable Segment Information	Reportable segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)	12 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities	The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows: September 30, 2021 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 9,718 $ 2 $ (1 ) $ 9,719 $ 7,717 $ 2,002 Total $ 9,718 $ 2 $ (1 ) $ 9,719 $ 7,717 $ 2,002 September 30, 2020 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ — Total $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ —
Components of Inventories	Inventories consisted of the following components: September 30, (In thousands) 2021 2020 Raw materials $ 4,165 $ 3,758 Work-in process 1,295 817 Finished products 1,300 1,391 Total $ 6,760 $ 5,966
Summary of Prepaids and Other Current Assets	Prepaids and other current assets consisted of the following: September 30, (In thousands) 2021 2020 Prepaid expenses $ 1,712 $ 1,418 Irish research and development credits receivable 1,164 1,177 CARES Act employee retention credit receivable 3,577 — Other — 775 Prepaids and other $ 6,453 $ 3,370
Schedule of Property, Plant and Equipment	Property and equipment consisted of the following components: Useful Life September 30, (Dollars in thousands) (Years) 2021 2020 Land N/A $ 4,419 $ 4,419 Laboratory fixtures and equipment 3 to 10 29,482 28,600 Buildings and improvements 3 to 20 26,573 25,638 Leasehold improvements 5 to 10 6,499 4,836 Office furniture and equipment 3 to 10 8,713 7,334 Construction-in-progress 2,120 2,238 Less: Accumulated depreciation (47,716 ) (42,962 ) Property and equipment, net $ 30,090 $ 30,103
Schedule of Intangible Assets	Intangible assets consisted of the following: September 30, 2021 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,216 $ (8,878 ) $ 4,338 Developed technology 11.9 36,531 (5,652 ) 30,879 Patents and other 14.1 3,551 (2,294 ) 1,257 Total definite-lived intangible assets 53,298 (16,824 ) 36,474 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 53,878 $ (16,824 ) $ 37,054 September 30, 2020 (Dollars in thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,356 $ (7,594 ) $ 5,762 Developed technology 11.5 9,685 (4,200 ) 5,485 Patents and other 14.1 3,551 (2,095 ) 1,456 Total definite-lived intangible assets 26,592 (13,889 ) 12,703 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 27,172 $ (13,889 ) $ 13,283
Estimated Amortization Expense	Based on the intangible assets in service as of September 30, 2021, estimated amortization expense for future fiscal years is as follows: (In thousands) 2022 $ 4,668 2023 4,070 2024 3,978 2025 3,940 2026 2,992 Thereafter 16,826 Definite-lived intangible assets $ 36,474
Schedule of Carrying Amount of Goodwill By Reportable Segment	Changes in the carrying amount of goodwill by segment were as follows: (In thousands) In Vitro Diagnostics Medical Device Total Goodwill as of September 30, 2019 $ 8,010 $ 18,161 $ 26,171 Foreign currency translation adjustment — 1,014 1,014 Goodwill as of September 30, 2020 8,010 19,175 27,185 Acquisition of Vetex Medical Limited — 19,089 19,089 Foreign currency translation adjustment — (668 ) (668 ) Goodwill as of September 30, 2021 $ 8,010 $ 37,596 $ 45,606
Summary of Other Noncurrent Assets	Other noncurrent assets consisted of the following: September 30, (In thousands) 2021 2020 Operating lease right-of-use assets $ 2,435 $ 2,508 Other noncurrent assets 1,283 1,761 Other assets, net $ 3,718 $ 4,269
Schedule of Accrued Other Liabilities	Accrued other liabilities consisted of the following: September 30, (In thousands) 2021 2020 Accrued professional fees $ 489 $ 239 Accrued clinical study expense 1,667 2,206 Accrued purchases 1,195 647 Acquisition of in-process research and development and intangible assets 494 1,148 Due to customers 112 321 Construction-in-progress 23 272 Operating lease liability, current portion 518 436 Other 407 278 Total accrued other liabilities $ 4,905 $ 5,547
Schedule of Other Long-term Liabilities	Other long-term liabilities consisted of the following: September 30, (In thousands) 2021 2020 Deferred consideration (1) $ 5,106 $ 2,216 Contingent consideration (2) 817 — Unrecognized tax benefits (3) 2,538 2,464 Operating lease liabilities 3,188 3,340 Other long-term liabilities $ 11,649 $ 8,020 (1) Deferred consideration consists of the present value of guaranteed payments to be made in connection with the fiscal 2021 Vetex acquisition (Note 12) and with in-process R&D technology asset acquisitions in fiscal 2019 and 2018 (Note 11). (2) Contingent consideration consists of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 5 and Note 12). (3) Balance of unrecognized tax benefits (Note 9) includes accrued interest and penalties, if applicable.
Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities	Operating lease right-of-use assets and lease liabilities were as follows: September 30, (In thousands) 2021 2020 Right-of-use assets: Other assets $ 2,435 $ 2,508 Operating lease liabilities: Other accrued liabilities $ 518 $ 436 Other long-term liabilities 3,188 3,340 Total operating lease liabilities $ 3,706 $ 3,776
Schedule of Operating Lease Maturities	As of September 30, 2021, operating lease maturities were as follows: (In thousands) 2022 $ 657 2023 671 2024 685 2025 699 2026 604 Thereafter 892 Total expected operating lease payments 4,208 Less: Imputed interest (502 ) Total operating lease liabilities $ 3,706
Denominator for Computation of Diluted Weighted Average Shares Outstanding	The following table presents the denominator for the computation of diluted weighted average shares outstanding: Fiscal Year (In thousands) 2021 2020 2019 Basic weighted average shares outstanding 13,765 13,552 13,389 Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units 224 260 390 Diluted weighted average shares outstanding 13,989 13,812 13,779

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Summary of Revenues Disaggregated by Product Classification and Reportable Segment	The following table presents the Company’s revenues disaggregated by product classification and by reportable segment: Fiscal Year (In thousands) 2021 2020 2019 Medical Device Product sales $ 21,777 $ 21,608 $ 18,617 Royalties 30,781 28,614 34,781 License fees 16,275 12,020 13,678 Research, development and other 9,420 9,159 11,277 Medical Device Revenue 78,253 71,401 78,353 In Vitro Diagnostics Product sales 24,701 22,709 21,390 Other 2,182 754 334 In Vitro Diagnostics Revenue 26,883 23,463 21,724 Total Revenue $ 105,136 $ 94,864 $ 100,077
Revenue from Customers	Revenue from customers that equaled or exceeded 10% of total revenue was as follows: Fiscal Year 2021 2020 2019 Abbott 21 % 19 % 19 % Medtronic 13 % 14 % 14 %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis by level of the fair value hierarchy were as follows: September 30, 2021 (In thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Assets Cash equivalents (1) $ — $ 5,308 $ — $ 5,308 Available-for-sale investments (1) — 9,719 — 9,719 Total assets $ — $ 15,027 $ — $ 15,027 Liabilities Contingent consideration (2) $ — $ — $ 817 $ 817 Total liabilities $ — $ — $ 817 $ 817 September 30, 2020 (In thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Assets Cash equivalents (1) $ — $ 18,634 $ — $ 18,634 Available-for-sale investments (1) — 30,313 — 30,313 Total assets $ — $ 48,947 $ — $ 48,947 (1) Fair value of cash equivalents (money market funds) and available-for-sale investments (commercial paper and corporate bond securities) is based on quoted vendor prices and broker pricing where all significant inputs are observable. (2) Fair value of contingent consideration liabilities was determined based on discounted cash flow analyses that included probability and timing of development and regulatory milestone achievements and a discount rate, which are considered significant unobservable inputs as of the acquisition date and as of September 30, 2021.
Schedule of Contingent Consideration Liabilities Measured at Fair Value	Changes in the contingent consideration liabilities measured at fair value using Level 3 inputs were as follows: (In thousands) Contingent consideration liability at September 30, 2019 $ 3,200 Additions — Fair value adjustments — Settlements (3,200 ) Interest accretion — Foreign currency translation — Contingent consideration liability at September 30, 2020 — Additions 814 Fair value adjustments — Settlements — Interest accretion 3 Foreign currency translation — Contingent consideration liability at September 30, 2021 $ 817

Stock-based Compensation Plans

Stock-based Compensation Plans (Tables)	12 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation Expenses	Stock-based compensation expense was reported as follows on the consolidated statements of operations: Fiscal Year (In thousands) 2021 2020 2019 Product costs $ 122 $ 119 $ 135 Research and development 1,298 896 876 Selling, general and administrative 4,443 4,438 4,066 Total stock-based compensation expense $ 5,863 $ 5,453 $ 5,077
Stock Option Fair Value Assumptions and Weighted Average Fair Value of Stock Options Granted	Stock option fair value assumptions and the weighted average fair value of stock options granted were as follows: Fiscal Year 2021 2020 2019 Stock option fair value assumptions: Risk-free interest rates 0.40 % 1.41 % 2.75 % Expected life (years) 4.6 4.6 4.5 Expected volatility 43 % 39 % 34 % Dividend yield — % — % — % Weighted average grant date fair value of stock options granted $ 14.71 $ 14.13 $ 17.89
Schedule of Stock Option Activity	Stock option activity was as follows: (In thousands, except per share data) Number of Shares Weighted Average Exercise Price Options outstanding at September 30, 2018 711 $ 26.28 Granted 179 55.09 Exercised (13 ) 22.03 Forfeited and expired (6 ) 42.28 Options outstanding at September 30, 2019 871 32.18 Granted 299 41.06 Exercised (125 ) 22.89 Forfeited and expired (105 ) 41.69 Options outstanding at September 30, 2020 940 35.18 Granted 274 40.95 Exercised (248 ) 24.22 Forfeited and expired (44 ) 44.58 Options outstanding at September 30, 2021 922 39.39 Options vested and exercisable at September 30, 2021 402 $ 36.07
Schedule of Restricted Stock Activity	Restricted Stock activity was as follows: (In thousands, except per share data) Number of Shares Weighted Average Grant Date Fair Value Unvested restricted stock awards at September 30, 2018 85 $ 30.30 Granted 45 56.05 Vested (39 ) 28.61 Forfeited (1 ) 47.86 Unvested restricted stock awards at September 30, 2019 90 43.69 Granted 67 41.40 Vested (43 ) 38.74 Forfeited (14 ) 44.76 Unvested restricted stock awards at September 30, 2020 100 44.16 Granted 71 38.83 Vested (48 ) 44.07 Forfeited (4 ) 40.45 Unvested restricted stock awards at September 30, 2021 119 $ 41.14

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of Income Taxes	Income taxes on the consolidated statements of operations consisted of the following: Fiscal Year (In thousands) 2021 2020 2019 Current provision (benefit): U.S. Federal $ 263 $ (1,570 ) $ 1,355 U.S. State 108 42 192 International 87 90 41 Total current provision (benefit) 458 (1,438 ) 1,588 Deferred provision (benefit): U.S. Federal 1,851 (1,336 ) (1,505 ) U.S. State (62 ) 197 (117 ) International (138 ) — — Total deferred benefit 1,651 (1,139 ) (1,622 ) Total income tax provision (benefit) $ 2,109 $ (2,577 ) $ (34 )
Schedule of Reconciliation Difference of Income Taxes	The difference between amounts calculated at the statutory U.S. federal income tax rate of 21% and the Company’s effective tax rate was as follows: Fiscal Year (In thousands) 2021 2020 2019 Amount at statutory U.S. federal income tax rate $ 1,333 $ (305 ) $ 1,587 Change because of the following items: State income taxes, net of federal benefit (273 ) (551 ) (452 ) U.S. federal and foreign R&D credits (920 ) (1,571 ) (2,464 ) Foreign and state rate differential 596 212 156 Valuation allowance change 1,059 825 671 Stock-based compensation (1) (544 ) (81 ) (163 ) Contingent consideration expense (gain) and related foreign currency revaluation 3 — (61 ) U.S. Federal and state rate change (35 ) 17 44 Tax reserve change (150 ) 609 770 Foreign-derived income deduction — (88 ) (150 ) Impact of CARES Act 735 (1,700 ) — Acquisition-related transaction costs 187 — — Other 118 56 28 Income tax provision (benefit) $ 2,109 $ (2,577 ) $ (34 ) (1) Includes non-deductible stock-based compensation.
Schedule of Deferred Income Taxes, Net	The components of deferred income taxes, net, consisted of the following and resulted from differences in the recognition of transactions for income tax and financial reporting purposes: September 30, (In thousands) 2021 2020 Depreciable assets $ (5,106 ) $ (1,964 ) Deferred revenue 2,130 2,029 Accruals and reserves 1,572 1,858 Stock-based compensation 1,997 2,232 Impaired strategic investments 1,782 1,767 NOL carryforwards 4,319 3,526 U.S. Federal and state R&D credits 3,066 3,216 Other 618 897 Valuation allowance (7,253 ) (6,246 ) Deferred taxes, net $ 3,125 $ 7,315
Summary of Reconciliation of Changes in Unrecognized Tax Benefits	Unrecognized tax benefits are the differences between a tax position taken, or expected to be taken in a tax return, and the benefit recognized for accounting purposes pursuant to accounting guidance. The following is a reconciliation of the changes in unrecognized tax benefits, excluding interest and penalties: Fiscal Year (In thousands) 2021 2020 2019 Unrecognized tax benefits, beginning balance $ 2,871 $ 2,323 $ 1,559 Increases in tax positions for prior years 15 58 278 Decreases in tax positions for prior years (8 ) (1 ) (2 ) Increases in tax positions for current year 458 664 735 Settlements with taxing authorities — — — Lapse of the statute of limitations (449 ) (173 ) (247 ) Unrecognized tax benefits, ending balance $ 2,887 $ 2,871 $ 2,323

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
Schedule of Acquisition Date Fair Value of Purchase Consideration	The acquisition date fair value of purchase consideration was as follows: (In thousands) Consideration paid at closing $ 39,985 Deferred consideration 3,257 Contingent consideration 814 Total purchase consideration 44,056 Less: Cash acquired (432 ) Total purchase consideration, net of cash acquired $ 43,624
Summary of Preliminary Allocation of Purchase Consideration	As of September 30, 2021, the preliminary allocation of purchase consideration was as follows: (In thousands) Asset (Liability) Current assets $ 66 Property and equipment 37 Intangible assets 27,600 Other non-current assets 133 Accrued compensation (236 ) Other accrued liabilities (111 ) Deferred income taxes (2,954 ) Net assets acquired 24,535 Goodwill 19,089 Total purchase consideration, net of cash acquired $ 43,624

Reportable Segment Information

Reportable Segment Information (Tables)	12 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Revenue, Operating Income (Loss) and Depreciation and Amortization	Segment revenue, operating income (loss), and depreciation and amortization were as follows: Fiscal Year (In thousands) 2021 2020 2019 Revenue: Medical Device $ 78,253 $ 71,401 $ 78,353 In Vitro Diagnostics 26,883 23,463 21,724 Total revenue $ 105,136 $ 94,864 $ 100,077 Operating income (loss): Medical Device $ 4,683 $ (3,246 ) $ 4,794 In Vitro Diagnostics 13,770 11,771 10,620 Total segment operating income 18,453 8,525 15,414 Corporate (11,750 ) (9,776 ) (8,945 ) Total operating income (loss) $ 6,703 $ (1,251 ) $ 6,469 Depreciation and amortization: Medical Device $ 7,224 $ 6,223 $ 5,811 In Vitro Diagnostics 395 483 464 Corporate 398 557 1,037 Total depreciation and amortization $ 8,017 $ 7,263 $ 7,312
Geographic Revenue and Long-lived Assets	Revenue by geographic region was as follows: Fiscal Year 2021 2020 2019 Domestic 79 % 78 % 81 % Foreign 21 % 22 % 19 % Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows: September 30, (In thousands) 2021 2020 U.S. $ 25,920 $ 25,273 Ireland 41,224 18,113

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Select Balance Sheet Information - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 9,718	$ 30,313
Unrealized Gains	2	19
Unrealized Losses	(1)	(19)
Fair Value	9,719	30,313
Current Assets	7,717	30,313
Noncurrent Assets	2,002
Commercial paper and corporate bonds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	9,718	30,313
Unrealized Gains	2	19
Unrealized Losses	(1)	(19)
Fair Value	9,719	30,313
Current Assets	7,717	$ 30,313
Noncurrent Assets	$ 2,002

Summary of Significant Accoun_5

Summary of Significant Accounting Policies and Select Balance Sheet Information - Additional Information (Detail) - USD ($) shares in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Oct. 01, 2019
Summary Of Significant Accounting Policies [Line Items]
Held-to-maturity debt securities	$ 0	$ 0
Realized gains or losses on sales of available-for-sale securities	0	0	$ 0
CARES Act employee retention credit, benefit to operating costs and expenses	3,600,000
CARES Act employee retention credit receivable	3,577,000	3,600,000
Depreciation expense	4,900,000	4,800,000	4,700,000
Amortization expense	3,100,000	2,500,000	2,600,000
Impairment loss	0	0
Goodwill impairment charges	0	0	0
Impairment charges relating to long-lived assets	$ 0	$ 0	$ 0
Antidilutive options excluded from computation of EPS	0.1	0.1	0.2
ASC Topic 842 adoption, right-of-use asset	$ 2,435,000	$ 2,508,000
ASC Topic 842 adoption, lease liability	3,706,000	3,776,000
Deferred rent liability		1,200,000
ASC Topic 842 [Member]
Summary Of Significant Accounting Policies [Line Items]
ASC Topic 842 adoption, right-of-use asset				$ 1,700,000
ASC Topic 842 adoption, lease liability				$ 2,900,000
Abbott Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Collaborative arrangement payment received	60,800,000
Collaborative arrangement additional potential milestone payments receivable	$ 30,000,000
Abbott Agreement [Member] | TRANSCEND Clinical Trial [Member]
Summary Of Significant Accounting Policies [Line Items]
Clinical study completion period	4 years
IDA [Member]
Summary Of Significant Accounting Policies [Line Items]
Reimbursement recorded as reduction to R&D expense		800,000	$ 700,000
Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Performance obligations, payment terms, royalties	45 days
Minimum [Member] | Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Performance obligations, payment terms, product sales	30 days
Performance obligations, payment terms, R&D services	30 days
Maximum [Member] | Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Performance obligations, payment terms, product sales	45 days
Performance obligations, payment terms, R&D services	45 days
Leases [Member]
Summary Of Significant Accounting Policies [Line Items]
Lease description	The Company leases facilities for research, office, manufacturing and warehousing.
Lease, existence of option to extend	true
Lease, option to extend	The Company’s leases include one or more options to renew and extend the lease term at the Company’s discretion. These renewal options are not included in right-of-use assets and lease liabilities as they are not reasonably certain of exercise.
Operating lease cost	$ 800,000	$ 600,000
Rent expense related to operating leases			500,000
Weighted average remaining lease term for operating leases	6 years 2 months 12 days
Weighted average discount rate used to determine operating lease liabilities	4.00%
Research and development expense [Member] | In-Process Research and Development [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss			$ 300,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies and Select Balance Sheet Information - Components of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 4,165	$ 3,758
Work-in process	1,295	817
Finished products	1,300	1,391
Total	$ 6,760	$ 5,966

Summary of Significant Accoun_7

Summary of Significant Accounting Policies and Select Balance Sheet Information - Summary of Prepaids and Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$ 1,712	$ 1,418
Irish research and development credits receivable	1,164	1,177
CARES Act employee retention credit receivable	3,577	3,600
Other		775
Prepaids and other	$ 6,453	$ 3,370

Summary of Significant Accoun_8

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Line Items]
Less: Accumulated depreciation	$ (47,716)	$ (42,962)
Property and equipment, net	30,090	30,103
Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	4,419	4,419
Laboratory Fixtures and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 29,482	28,600
Laboratory Fixtures and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	3 years
Laboratory Fixtures and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	10 years
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 26,573	25,638
Building and Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	3 years
Building and Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	20 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 6,499	4,836
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	5 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	10 years
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 8,713	7,334
Office Furniture and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	3 years
Office Furniture and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	10 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 2,120	$ 2,238

Summary of Significant Accoun_9

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (16,824)	$ (13,889)
Definite-lived intangible assets, Net	36,474
Intangible assets, Gross Carrying Amount	53,878	27,172
Intangible assets, Net	$ 37,054	$ 13,283
Customer Lists and Relationships [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years 10 months 24 days	8 years 10 months 24 days
Definite-lived intangible assets, Gross Carrying Amount	$ 13,216	$ 13,356
Definite-lived intangible assets, Accumulated Amortization	(8,878)	(7,594)
Definite-lived intangible assets, Net	$ 4,338	$ 5,762
Developed Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	11 years 10 months 24 days	11 years 6 months
Definite-lived intangible assets, Gross Carrying Amount	$ 36,531	$ 9,685
Definite-lived intangible assets, Accumulated Amortization	(5,652)	(4,200)
Definite-lived intangible assets, Net	$ 30,879	$ 5,485
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	14 years 1 month 6 days	14 years 1 month 6 days
Definite-lived intangible assets, Gross Carrying Amount	$ 3,551	$ 3,551
Definite-lived intangible assets, Accumulated Amortization	(2,294)	(2,095)
Definite-lived intangible assets, Net	1,257	1,456
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	53,298	26,592
Definite-lived intangible assets, Accumulated Amortization	(16,824)	(13,889)
Definite-lived intangible assets, Net	36,474	12,703
Trademarks and Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 580	$ 580

Summary of Significant Accou_10

Summary of Significant Accounting Policies and Select Balance Sheet Information - Estimated Amortization Expense (Detail) $ in Thousands	Sep. 30, 2021USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
2022	$ 4,668
2023	4,070
2024	3,978
2025	3,940
2026	2,992
Thereafter	16,826
Definite-lived intangible assets, Net	$ 36,474

Summary of Significant Accou_11

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Carrying Amount of Goodwill by Reportable Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Goodwill [Line Items]
Goodwill as of September 30, 2019	$ 27,185	$ 26,171
Acquisition of Vetex Medical Limited	19,089
Foreign currency translation adjustment	(668)	1,014
Goodwill as of September 30, 2020	45,606	27,185
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Goodwill as of September 30, 2019	8,010	8,010
Goodwill as of September 30, 2020	8,010	8,010
Medical Device [Member]
Goodwill [Line Items]
Goodwill as of September 30, 2019	19,175	18,161
Acquisition of Vetex Medical Limited	19,089
Foreign currency translation adjustment	(668)	1,014
Goodwill as of September 30, 2020	$ 37,596	$ 19,175

Summary of Significant Accou_12

Summary of Significant Accounting Policies and Select Balance Sheet Information - Summary of Other Noncurrent Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Schedule of Investments [Line Items]
Other assets, net	$ 3,718	$ 4,269
Operating Lease Right-of-Use Assets [Member]
Schedule of Investments [Line Items]
Other assets, net	2,435	2,508
Other Noncurrent Assets [Member]
Schedule of Investments [Line Items]
Other assets, net	$ 1,283	$ 1,761

Summary of Significant Accou_13

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Accrued Other Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 489	$ 239
Accrued clinical study expense	1,667	2,206
Accrued purchases	1,195	647
Acquisition of in-process research and development and intangible assets	494	1,148
Due to customers	112	321
Construction-in-progress	23	272
Operating lease liability, current portion	518	436
Other	407	278
Total accrued other liabilities	$ 4,905	$ 5,547

Summary of Significant Accou_14

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Other Long-term Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Other Liabilities Disclosure [Abstract]
Deferred consideration	$ 5,106	$ 2,216
Contingent consideration	817
Unrecognized tax benefits	2,538	2,464
Operating lease liabilities	3,188	3,340
Other long-term liabilities	$ 11,649	$ 8,020

Summary of Significant Accou_15

Summary of Significant Accounting Policies and Select Balance Sheet Information - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Right-of-use assets:
Other assets	$ 2,435	$ 2,508
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherAssets
Operating lease liabilities:
Other accrued liabilities	$ 518	436
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherLiabilitiesCurrent
Operating lease liabilities	$ 3,188	3,340
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities
Total operating lease liabilities	$ 3,706	$ 3,776

Summary of Significant Accou_16

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Operating Lease Maturities (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Operating Lease Liabilities Payments Due [Abstract]
2022	$ 657
2023	671
2024	685
2025	699
2026	604
Thereafter	892
Total expected operating lease payments	4,208
Less: Imputed interest	(502)
Total operating lease liabilities	$ 3,706	$ 3,776

Summary of Significant Accou_17

Summary of Significant Accounting Policies and Select Balance Sheet Information - Denominator for Computation of Diluted Weighted Average Shares Outstanding (Detail) - shares shares in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Basic weighted average shares outstanding	13,765	13,552	13,389
Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units	224	260	390
Diluted weighted average shares outstanding	13,989	13,812	13,779

Revenue - Summary of Revenues D

Revenue - Summary of Revenues Disaggregated by Product Classification and Reportable Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Disaggregation Of Revenue [Line Items]
Total revenue	$ 105,136	$ 94,864	$ 100,077
Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	46,478	44,317	40,219
Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	47,056	40,634	48,458
Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	11,602	9,913	11,400
Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	105,136	94,864	100,077
Operating Segments [Member] | Medical Device [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	78,253	71,401	78,353
Operating Segments [Member] | Medical Device [Member] | Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	21,777	21,608	18,617
Operating Segments [Member] | Medical Device [Member] | Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	30,781	28,614	34,781
Operating Segments [Member] | Medical Device [Member] | License Fees [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	16,275	12,020	13,678
Operating Segments [Member] | Medical Device [Member] | Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	9,420	9,159	11,277
Operating Segments [Member] | In Vitro Diagnostics [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	26,883	23,463	21,724
Operating Segments [Member] | In Vitro Diagnostics [Member] | Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	24,701	22,709	21,390
Operating Segments [Member] | In Vitro Diagnostics [Member] | Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 2,182	$ 754	$ 334

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Contract assets — royalties and license fees	$ 7,091	$ 6,108

Revenue - Revenue from Customer

Revenue - Revenue from Customers (Detail) - Revenue [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Abbott [Member]
Entity Wide Revenue Major Customer [Line Items]
Percentage of revenue	21.00%	19.00%	19.00%
Medtronic [Member]
Entity Wide Revenue Major Customer [Line Items]
Percentage of revenue	13.00%	14.00%	14.00%

Collaborative Arrangement - Add

Collaborative Arrangement - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue	$ 105,136,000	$ 94,864,000	$ 100,077,000
Abbott Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement payment received	60,800,000
Collaborative arrangement additional potential milestone payments receivable	30,000,000
Total revenue	16,000,000	12,000,000	13,500,000
Upfront and milestone fee payment included in deferred revenue	14,900,000	15,900,000
Collaboration revenue recognized included in balance at beginning of period	4,700,000	5,000,000	8,400,000
Abbott Agreement [Member] | Contract Life to Date [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue	45,900,000
Abbott Agreement [Member] | Upfront Payment [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement payment received				$ 25,000,000
Abbott Agreement [Member] | Milestone Payment [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement payment received	15,000,000	$ 10,800,000	$ 10,000,000
Abbott Agreement [Member] | Maximum [Member] | PMA Milestone [Member] | TRANSCEND Clinical Trial [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement additional potential milestone payments receivable	$ 30,000,000

Collaborative Arrangement - A_2

Collaborative Arrangement - Additional Information (Detail 1) - Abbott Agreement [Member]	12 Months Ended
	Sep. 30, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-10-01
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligation, expected timing of satisfaction, period	four years
Remaining performance obligation, expected timing of satisfaction, percentage	83.00%
Revenue remaining performance obligation expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-10-01
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligation, expected timing of satisfaction, percentage	17.00%
Revenue remaining performance obligation expected timing of satisfaction period	3 years

Collaborative Arrangement - A_3

Collaborative Arrangement - Additional Information (Detail 2) $ in Millions	Sep. 30, 2021USD ($)
Abbott Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligation, amount	$ 14.9

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Member] - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 15,027	$ 48,947
Liabilities measured at fair value	817
Available-for-sale investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	9,719	30,313
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	15,027	48,947
Significant Other Observable Inputs (Level 2) [Member] | Available-for-sale investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	9,719	30,313
Level 3 Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	817
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	5,308	18,634
Cash equivalents [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	5,308	$ 18,634
Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	817
Contingent consideration [Member] | Level 3 Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	$ 817

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Contingent Consideration Liabilities Measured at Fair Value (Detail) - Contingent Consideration [Member] - Significant Unobservable Inputs (Level 3) [Member] - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Contingent consideration liability, beginning balance		$ 3,200
Additions	$ 814
Settlements		$ (3,200)
Interest accretion	3
Contingent consideration liability, ending balance	$ 817

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2019
NorMedix [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability		$ 3.2
Vetex Medical Limited [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability	$ 0.8

Debt - Additional Information (

Debt - Additional Information (Details) - Secured Revolving Credit Facility [Member] - Loan and Security Agreement [Member] - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 14, 2020
Line Of Credit Facility [Line Items]
Revolving credit facility, maximum borrowing capacity			$ 25,000,000
Revolving credit facility, outstanding balance	$ 10,000,000	$ 0
Revolving credit facility, borrowing base	Availability under the Revolving Credit Facility is subject to a borrowing base that equals 80% of the margin value of securities collateral that has been pledged to Bridgewater.
Revolving credit facility, maturity date	Sep. 14, 2022	Sep. 14, 2021
Debt instrument, maturity date, description	The maturity date may be extended by the Company for up to one additional extension period of twelve months subject to certain conditions set forth in the Loan Agreement.
Revolving credit facility, interest rate	Interest under the Loan Agreement accrues at a rate per annum equal to the greater of (i) 3.25% per annum and (ii) the 90-day interest rate yield for U.S. Government Treasury Securities plus 2.75% per annum.
Revolving credit facility, basis spread on variable rate	2.75%
Revolving credit facility, unused commitment fee rate	0.075%
Revolving credit facility, frequency of payments	quarterly
Interest Expense [Member]
Line Of Credit Facility [Line Items]
Revolving credit facility, unused commitment fee	$ 100,000
Minimum [Member]
Line Of Credit Facility [Line Items]
Revolving credit facility, interest rate	3.25

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2021	Nov. 06, 2015	Nov. 05, 2014
Stockholders Equity [Line Items]
Remaining amount available for repurchases of shares	$ 25.3
Accelerated Share Repurchase Program [Member]
Stockholders Equity [Line Items]
Maximum payments for repurchase of common stock		$ 20	$ 30

Stock-based Compensation Plan_2

Stock-based Compensation Plans - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 5,863	$ 5,453	$ 5,077
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	122	119	135
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,298	896	876
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,443	$ 4,438	$ 4,066

Stock-based Compensation Plan_3

Stock-based Compensation Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2018
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs, nonvested awards, amount	$ 8,400,000
Unrecognized compensation costs, nonvested awards, weighted average recognition period	2 years 2 months 12 days
Stock-based compensation expense	$ 5,863,000	$ 5,453,000	$ 5,077,000
Dividend yield		0.00%
Nonqualified Stock Options [Member]
Stock-Based Compensation Activity [Line Items]
Expiration period	7 years
Stock-based compensation expense	$ 2,800,000	$ 2,500,000	2,200,000
Aggregate intrinsic value, outstanding options	15,100,000
Aggregate intrinsic value, exercisable options	$ 7,900,000
Weighted average remaining contractual life, options outstanding	4 years 7 months 6 days
Weighted average remaining contractual remaining, options exercisable	3 years 4 months 24 days
Intrinsic value, options exercised	$ 7,100,000	2,000,000	300,000
Nonqualified Stock Options [Member] | Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	4 years
Nonqualified Stock Options [Member] | Maximum [Member] | Director [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	1 year
Restricted Stock Awards [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	3 years
Stock-based compensation expense	$ 2,200,000	$ 2,000,000	$ 1,700,000
Units granted	71,000	67,000	45,000
Units outstanding	119,000	100,000	90,000			85,000
Weighted average grant date fair value	$ 44.07	$ 38.74	$ 28.61
Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period	3 years
Stock-based compensation expense	$ 500,000	$ 600,000	$ 600,000
Units granted	17,000	18,000	12,000
Units outstanding	61,000	65,000
Weighted average grant date fair value	$ 33.45	$ 31.12
Deferred Stock Units [Member] | Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock-based compensation expense	$ 100,000	$ 100,000	$ 100,000
Units outstanding	34,000	33,000
Weighted average grant date fair value	$ 30.32	$ 28.41
Performance Shares [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period				3 years	3 years
Performance Shares [Member] | Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of stock units granted				$ 1,200,000
Performance Shares [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Stock-based compensation expense	$ 0	$ 100,000	400,000
1999 Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock-based compensation expense	200,000	100,000	$ 100,000
Annual compensation withheld, maximum limit	25,000
Employee contributions in accrued compensation at period end	$ 100,000	$ 100,000
1999 Employee Stock Purchase Plan [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Common stock authorized, original authorization	600,000
Annual compensation withheld	10.00%
Vesting Anniversary [Member] | Nonqualified Stock Options [Member] | Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage	25.00%
Vesting Anniversary [Member] | Restricted Stock Awards [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage	33.00%
Vesting Anniversary [Member] | Restricted Stock Units (RSUs) [Member] | Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage	33.00%
2019 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Common stock authorized, original authorization	1,100,000
Common stock authorized, shares remaining	485,000

Stock-based Compensation Plan_4

Stock-based Compensation Plans - Stock Option Fair Value Assumptions and Weighted Average Fair Value of Stock Options Granted (Detail) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Stock option fair value assumptions:
Risk-free interest rates	0.40%	1.41%	2.75%
Expected life (years)	4 years 7 months 6 days	4 years 7 months 6 days	4 years 6 months
Expected volatility	43.00%	39.00%	34.00%
Dividend yield		0.00%
Weighted average grant date fair value of stock options granted	$ 14.71	$ 14.13	$ 17.89

Stock-based Compensation Plan_5

Stock-based Compensation Plans - Schedule of Stock Option Activity (Detail) - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options Outstanding, Beginning balance	940,000	871,000	711,000
Number of Options, Granted	274,000	299,000	179,000
Number of Options, Exercised	(248,000)	(125,000)	(13,000)
Number of Options, Forfeited and expired	(44,000)	(105,000)	(6,000)
Number of Options Outstanding, Ending balance	922,000	940,000	871,000
Number of Options, vested and exercisable	402,000
Weighted Average Exercise Price, Beginning Balance	$ 35.18	$ 32.18	$ 26.28
Weighted Average Exercise Price, Granted	40.95	41.06	55.09
Weighted Average Exercise Price, Exercised	24.22	22.89	22.03
Weighted Average Exercise Price, Forfeited and expired	44.58	41.69	42.28
Weighted Average Exercise Price, Ending balance	39.39	$ 35.18	$ 32.18
Weighted Average Exercise Price, vested and exercisable	$ 36.07

Stock-based Compensation Plan_6

Stock-based Compensation Plans - Schedule of Restricted Stock Activity (Detail) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Units, Beginning balance	100,000	90,000	85,000
Number of Units, Granted	71,000	67,000	45,000
Number of Units, Vested	(48,000)	(43,000)	(39,000)
Number of Units, Forfeited	(4,000)	(14,000)	(1,000)
Number of Units, Ending balance	119,000	100,000	90,000
Weighted Average Grant Date Fair Value, Beginning balance	$ 44.16	$ 43.69	$ 30.30
Weighted Average Grant Date Fair Value, Granted	38.83	41.40	56.05
Weighted Average Grant Date Fair Value, Vested	44.07	38.74	28.61
Weighted Average Grant Date Fair Value, Forfeited	40.45	44.76	47.86
Weighted Average Grant Date Fair Value, Ending balance	$ 41.14	$ 44.16	$ 43.69

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Current provision (benefit):
U.S. Federal	$ 263	$ (1,570)	$ 1,355
U.S. State	108	42	192
International	87	90	41
Total current provision (benefit)	458	(1,438)	1,588
Deferred provision (benefit):
U.S. Federal	1,851	(1,336)	(1,505)
U.S. State	(62)	197	(117)
International	(138)
Total deferred benefit	1,651	(1,139)	(1,622)
Total income tax provision (benefit)	$ 2,109	$ (2,577)	$ (34)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2017
Income Tax Disclosure [Line Items]
U.S. federal statutory tax rate	21.00%	21.00%		35.00%
Impact of CARES Act	$ (735,000)	$ 1,700,000
Excess tax benefits related to stock based compensation expense	900,000	400,000	$ 500,000
Deferred tax asset valuation allowance	7,253,000	6,246,000
Unrecognized tax benefits that would impact effective tax rate	2,700,000	2,700,000	2,100,000
Accrued interest and penalties on unrecognized tax benefits	400,000	600,000	$ 500,000
Undistributed earnings in foreign subsidiaries	0	$ 0
Federal [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 100,000
Net operating loss carryforwards, beginning of expiration year	Jan. 1, 2035
State [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 100,000
Net operating loss carryforwards, beginning of expiration year	Jan. 1, 2029
Ireland and Luxembourg [Member] | Creagh Medical Ltd [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards	$ 4,100,000
R&D Credit Carryforwards [Member] | Federal and State [Member] | 2029 [Member]
Income Tax Disclosure [Line Items]
Tax credit carryforwards	$ 3,100,000
Tax credit carryforward, beginning of expiration year	Jan. 1, 2029

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation Difference of Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Amount at statutory U.S. federal income tax rate	$ 1,333	$ (305)	$ 1,587
Change because of the following items:
State income taxes, net of federal benefit	(273)	(551)	(452)
U.S. federal and foreign R&D credits	(920)	(1,571)	(2,464)
Foreign and state rate differential	596	212	156
Valuation allowance change	1,059	825	671
Stock-based compensation	(544)	(81)	(163)
Contingent consideration expense (gain) and related foreign currency revaluation	3		(61)
U.S. Federal and state rate change	(35)	17	44
Tax reserve change	(150)	609	770
Foreign-derived income deduction		(88)	(150)
Impact of CARES Act	735	(1,700)
Acquisition-related transaction costs	187
Other	118	56	28
Total income tax provision (benefit)	$ 2,109	$ (2,577)	$ (34)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Taxes, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Depreciable assets	$ (5,106)	$ (1,964)
Deferred revenue	2,130	2,029
Accruals and reserves	1,572	1,858
Stock-based compensation	1,997	2,232
Impaired strategic investments	1,782	1,767
NOL carryforwards	4,319	3,526
U.S. Federal and state R&D credits	3,066	3,216
Other	618	897
Valuation allowance	(7,253)	(6,246)
Deferred taxes, net	$ 3,125	$ 7,315

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Changes in Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Unrecognized tax benefits, beginning balance	$ 2,871	$ 2,323	$ 1,559
Increases in tax positions for prior years	15	58	278
Decreases in tax positions for prior years	(8)	(1)	(2)
Increases in tax positions for current year	458	664	735
Lapse of the statute of limitations	(449)	(173)	(247)
Unrecognized tax benefits, ending balance	$ 2,887	$ 2,871	$ 2,323

Defined Contribution Plans - Ad

Defined Contribution Plans - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Defined Contribution Plan Disclosure [Line Items]
Contributions to defined contribution plans	$ 1.1	$ 1	$ 0.9
U.S. [Member] | 401 (K) Retirement and Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Percentage of employee contributions, eligible for employer match	50.00%
Percentage of employee contributions	6.00%
Ireland [Member] | Defined Contribution PRSA Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Percentage of employee contributions, eligible for employer match	6.00%
Percentage of employee contributions	8.00%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	12 Months Ended				24 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2024
Commitments And Contingencies [Line Items]
Payments to acquire in-process research and development			$ 750,000
Acquisition charge for in-process of research and development			890,000
Other long-term liabilities	$ 11,649,000	$ 8,020,000
Other accrued liabilities current	407,000	278,000
Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Contingent payments upon achievement of regulatory milestones	$ 1,000,000
Installment payment beginning period	2022
Installment payment ending period	2024
CRO [Member]
Commitments And Contingencies [Line Items]
Contractual obligation remaining to be paid	$ 7,000,000
CRO [Member] | Minimum [Member]
Commitments And Contingencies [Line Items]
Gross contractual obligation	37,000,000
CRO [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Gross contractual obligation	40,000,000
CRO [Member] | Maximum [Member] | CRO Pass-through Expenses [Member]
Commitments And Contingencies [Line Items]
Gross contractual obligation	29,000,000
In-Process Research and Development [Member] | Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Payments to acquire in-process research and development	$ 1,000,000	1,000,000		$ 5,000,000
Contingency period ending year	2033
Contingent obligation due and payable as a result of achievement of regulatory milestone(s)	$ 1,000,000
Other long-term liabilities	6,400,000	2,200,000
Other accrued liabilities current		$ 1,100,000
In-Process Research and Development [Member] | Embolitech LLC [Member] | Forecast [Member]
Commitments And Contingencies [Line Items]
Contractual obligation payable in fiscal 2022 through fiscal 2024					$ 2,500,000
In-Process Research and Development [Member] | Medical Device [Member]
Commitments And Contingencies [Line Items]
Payments to acquire in-process research and development	$ 200,000		800,000
Contingent payments upon achievement of regulatory milestones			1,100,000
Contingency period ending year	2022
Acquisition charge for in-process of research and development			$ 900,000

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($)	Jul. 02, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition [Line Items]
Revenue		$ 105,136,000	$ 94,864,000	$ 100,077,000
Net (loss) income		4,237,000	$ 1,123,000	$ 7,592,000
Acquisition transaction, integration and other costs		1,049,000
Vetex Medical Limited [Member]
Business Acquisition [Line Items]
Cash paid	$ 39,900,000
Deferred consideration, contractual value	$ 3,500,000
Installment payment beginning period	2024
Installment payment ending period	2027
Contingent consideration, contractual value	$ 3,500,000
Contingency period ending year	2027
Revenue		0
Net (loss) income		(900,000)
Acquisition transaction, integration and other costs		$ 1,000,000
Vetex Medical Limited [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Acquired intangible assets amortized on straight-line basis, estimated useful life		12 years
Vetex Medical Limited [Member] | Secured Revolving Credit Facility [Member]
Business Acquisition [Line Items]
Business combination, consideration transferred, liabilities incurred	$ 10,000,000

Acquisitions - Summary of Acqui

Acquisitions - Summary of Acquisition Date Fair Value of Purchase Consideration (Detail) - Vetex Medical Limited [Member] $ in Thousands	Jul. 02, 2021USD ($)
Business Acquisition [Line Items]
Consideration paid at closing	$ 39,985
Deferred consideration	3,257
Contingent consideration	814
Total purchase consideration	44,056
Less: Cash acquired	(432)
Total purchase consideration, net of cash acquired	$ 43,624

Acquisitions - Summary of Preli

Acquisitions - Summary of Preliminary Allocation of Purchase Consideration (Detail) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition [Line Items]
Goodwill	$ 45,606	$ 27,185	$ 26,171
Vetex Medical Limited [Member]
Business Acquisition [Line Items]
Current assets	66
Property and equipment	37
Intangible assets	27,600
Other non-current assets	133
Accrued compensation	(236)
Other accrued liabilities	(111)
Deferred income taxes	(2,954)
Net assets acquired	24,535
Goodwill	19,089
Total purchase consideration, net of cash acquired	$ 43,624

Reportable Segment Informatio_2

Reportable Segment Information - Additional Information (Detail)	12 Months Ended
	Sep. 30, 2021Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Reportable Segment Informatio_3

Reportable Segment Information - Segment Revenue, Operating Income (Loss) and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 105,136	$ 94,864	$ 100,077
Operating (loss) income	6,703	(1,251)	6,469
Depreciation and amortization	8,017	7,263	7,312
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	105,136	94,864	100,077
Operating (loss) income	18,453	8,525	15,414
Operating Segments [Member] | Medical Device [Member]
Segment Reporting Information [Line Items]
Revenue	78,253	71,401	78,353
Operating (loss) income	4,683	(3,246)	4,794
Depreciation and amortization	7,224	6,223	5,811
Operating Segments [Member] | In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	26,883	23,463	21,724
Operating (loss) income	13,770	11,771	10,620
Depreciation and amortization	395	483	464
Corporate [Member]
Segment Reporting Information [Line Items]
Operating (loss) income	(11,750)	(9,776)	(8,945)
Depreciation and amortization	$ 398	$ 557	$ 1,037

Reportable Segment Informatio_4

Reportable Segment Information - Geographic Revenue and Long-lived Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, net	$ 25,920	$ 25,273
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, net	$ 41,224	$ 18,113
Revenue [Member] | Geographic Concentration Risk [Member] | Domestic [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Percentage of consolidated revenue	79.00%	78.00%	81.00%
Revenue [Member] | Geographic Concentration Risk [Member] | Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Percentage of consolidated revenue	21.00%	22.00%	19.00%

Schedule of Valuation and Qua_2

Schedule of Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Detail) - Allowance for doubtful accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 130	$ 200	$ 147
Additions: Charges to Income	(11)	73	188
Deductions: Other Changes (Debit) Credit		(143)	(135)
Balance at End of Period	$ 119	$ 130	$ 200